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S-Adenosylmethionine decarboxylase (AdoMetDC) is a critical enzyme in the polyamine biosynthetic pathway
and depends on a pyruvoyl group for the decarboxylation process. The crystal structures of the enzyme
with various inhibitors at the active site have shown that the adenine base of the ligands adopts an unusual
syn conformation when bound to the enzyme. To determine whether compounds that favor the syn
conformation in solution would be more potent AdoMetDC inhibitors, several series of AdoMet substrate
analogues with a variety of substituents at the 8-position of adenine were synthesized and analyzed for their
ability to inhibit hAdoMetDC. The biochemical analysis indicated that an 8-methyl substituent resulted in
more potent inhibitors, yet most other 8-substitutions provided no beneﬁt over the parent compound. To
understand these results, we used computational modeling and X-ray crystallography to study C8-substituted
adenine analogues bound in the active site.
Introduction
S-Adenosylmethionine decarboxylase (AdoMetDC
a)i sa
pyruvoyl dependent decarboxylase and a critical enzyme in the
polyamine biosynthetic pathway, which is found in mammals,
Protista, and many other species.
1-4 The polyamines putrescine,
spermidine, and spermine are essential for cell growth and play
important roles in cell proliferation and differentiation.
5-7
Polyamines have been found to be elevated in various types of
cancer including non-small-cell lung cancer, prostate cancer,
melanoma, and pancreatic cancer.
8,9 Polyamine levels in cells
depend on the polyamine biosynthetic and catabolic pathways
as well as on import and export of polyamines across the cellular
membrane. Altering regulation of the key enzymes in the
polyamine pathway is a therapeutic strategy for treatment of
various types of cancers. AdoMetDC catalyzes the conversion
of S-adenosylmethionine (AdoMet) to decarboxylated S-adeno-
sylmethionine (dcAdoMet), which then donates the aminopropyl
group to putrescine or spermidine to form spermidine and
spermine, respectively. AdoMetDC is at a key branch point in
the pathway and its action commits AdoMet to polyamine
biosynthesis and removes it from the pool available for methyl
transfer to a variety of substrates.
Attempts to regulate polyamine levels have resulted in the
development of inhibitors that target the biosynthetic enzymes
ornithine decarboxylase (ODC),
10 AdoMetDC, and the catabolic
enzyme spermidine/spermine N1-acetyltransferase (SSAT).
11 The
best-known inhibitor of ODC is R-diﬂuoromethylornithine
(DFMO), which irreversibly inactivates the enzyme. The success
of DFMO in cancer therapy has been limited as the cells
compensate for the decreased synthesis of polyamines through
increased cellular uptake of polyamines.
12 DFMO is currently
being investigated as a chemopreventive agent against carcino-
genesis.
13-17 The development of drugs to inhibit AdoMetDC
(Figure 1A) started with the competitive inhibitor methylglyoxal
bis(guanylhydrazone) 1 (MGBG), which is similar to spermidine
in structure.
18 Use of 1 caused extreme toxicity in humans, and
many analogues of 1 were developed in attempts to decrease
the toxicity. One such AdoMetDC inhibitor that resulted was
4-amidinoindan-1-one-2′ -amidinohydrazone 2 (CGP48664A
19),
which progressed into clinical trials as a cancer chemothera-
peutic agent.
19 Alternatively, inhibitors such as 5′ -deoxy-5′ -[(3-
hydrazinopropyl)methylamino]adenosine 3(MHZPA), 5′ -deoxy-
5′ -[(3-hydrazinoethyl)methylamino)adenosine 4 (MHZEA),
and 5′ -[(2-aminooxyethyl)methylamino]-5′ -deoxyadenosine
5 (MAOEA), which are structural analogues of the natural
substrate, were developed (Figure 1B). These compounds
inactivate AdoMetDC by forming a Schiff base to the active
site pyruvoyl group.
20 Another known nucleoside inhibitor
of AdoMetDC is 5′ -[[(Z)-4-amino-2-butenyl]methylamino]-
† The Protein Data Bank codes for the complexes are under the following
accession numbers: wild type AdoMetDC with 12a (3DZ5), 14e (3DZ6),
17d (3DZ4), 17f (3DZ7) and 21c (3DZ2), and F223A mutant AdoMetDC
with MeAdoMet (3DZ3).
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an enzyme-activated irreversible inhibitor,
21 but subsequent
experiments showed that it acted via transamination of the
pyruvate prosthetic group.
20
The crystal structure of AdoMetDC and its S68A and H243A
mutants were solved to aid understanding of the mechanisms
of decarboxylation and autoprocessing.
22-24 The crystal struc-
tures of AdoMetDC with inhibitors like 5, 3, and the methyl
ester of S-adenosylmethionine (MeAdoMet) have been solved
previously.
25 These structures show that the adenine base of
the inhibitors assumes an unusual syn conformation within the
active site. The preference for the unusual conformation has
led us to develop new structural analogues of AdoMet with
modiﬁcations on the adenine base and to investigate, through
biochemical analysis, computational modeling and analysis of
crystal structures, whether these compounds would be more
potent inhibitors of AdoMetDC than the unsubstituted parent
compounds. Substitution at the 8-position of adenine is expected
to result in ligands that favor the syn conformation in solution,
and it was hoped that this would increase their ability to inhibit
AdoMetDC. We now describe the synthesis of several series
of structural analogues of AdoMet with 8-substituted adenine
and present AdoMetDC inhibition data. We report the crystal
structures of the AdoMetDC F223A mutant complexed with
MeAdoMet and the wild-type protein complexed with several
8-substituted inhibitors.
Results
Chemical Synthesis. Our synthetic efforts relating to AdoMet-
DC date back many years, when we prepared an early series of
related compounds that included 3 and 5.
26 In our current
research, we have prepared a series of compounds with various
8-substituents on an adenosine template having a chain extension
at C-5′ . These compounds fall into four broad categories with
respect to the various substituents at C-5′ , and synthetic schemes
will be organized based upon these categories. For comparison
purposes, we have included available compounds with an 8-H
within the four categories. End groups of the C-5′ substituent
such as an aminooxyalkyl will bind covalently and to a large
extent irreversibly to the pyruvoyl group within the active site
of the enzyme, while groups ending in an amide will not even
bind reversibly covalently to the pyruvoyl group. Amino end
groups will bind covalently, but entirely reversibly, while a
hydrazide group binds with some reversibility. In addition to
these compounds, we have prepared several compounds without
a chain extension at C-5′ , i.e., compounds that do not reach the
vicinity of the pyruvate group within the binding site.
The syntheses of some of the 8-unsubstituted compounds date
back to our earlier work,
26 and these compounds dictated our
initial synthetic approaches. We began by assuming that we
needed to block the 2′ - and 3′ -hydroxyl groups, which we did
with an isopropylidene group. Later, we discovered that it was
possible to conduct the chemistry without blocking these two
hydroxyl groups and that the new schemes were superior to
those that utilized a blocking-deblocking sequence. In situations
where we had already prepared a target compound utilizing a
blocked precursor, we did not go back and resynthesize the
compound without using a blocking group, and the schemes
below reﬂect that fact. Scheme 1 presents the precursor
nucleoside series 8 and 9 that we have used along with their
syntheses.
Target compounds with an aminooxyalkylamino side chain
at C-5′ were prepared using two different routes, as shown in
Scheme 2. In our original sequence, which utilized a 2′ ,3′ -O-
isopropylidene group for protection, we generated the hydroxy-
alkylamino precursor 15 by displacement of a tosyl group with
the requisite amine. Using N-hydroxyphthalimide, triphenylphos-
phine, and DEAD,
27 the aminooxy precursor 16 was produced
and then converted to the desired target 5 under acidic
conditions. Later, we found that it was more effective to ﬁrst
generate the aminooxy precursors ethyl N-(2-bromoethoxy)
ethanimidate
28 and ethyl N-(N-4-bromobutoxy)ethanimidate
29
(Scheme 2), which could be appended to C-5′ by halide
displacement with a 5′ -methylamino-5′ -deoxynucleoside to
produce product series 11 and 13. Initially, we carried out this
displacement with an isopropylidene protecting group on the
nucleoside but subsequently determined that the reaction works
as well or better without the protecting group. By the above
means targets 12a-c and 14a-f were prepared.
All of the amides and hydrazides were made by similar
procedures, as shown in Scheme 3. The 5′ -methylamino-5′ -
deoxynucleosides were treated with the appropriate ω-chlo-
roester, followed by treatment with either ammonia or hydrazine.
If an isopropylidene group was involved, then it was removed
with an acidic deprotection step. In this manner targets 17d-f,
j-m, with two different linker lengths and various 8-substitu-
ents, were prepared.
Targets with an aminoalkylamino side chain at C-5′ were
mainly prepared utilizing the displacement of a C-5′ leaving
group with the unsymmetrical amine (Scheme 4). For example,
treatment of 8a with 3-methylaminoethylamine produced a
mixture of 18f and 19d, which were separated to afford pure
18f, our desired target. In the case where this procedure involved
a starting material with an isopropylidene group, treatment with
acid produced the desired ﬁnal product. In early work, com-
pounds 21c,d were prepared by treatment of a 5′ -methylamino-
5′ -deoxynucleoside with 3-bromopropylphthalimide followed by
two deprotection steps.
Building on the aminoalkylamino side chain, reaction of 18e
with 1-carboxamidinopyrazole
30 produced the guanidine target
22a. In a related sequence, the target amidoxime 22c was
prepared by treating 8j with 3-(methylamino)propionitrile to
produce the nitrile 22b,
31 which was treated with hydroxylamine
hydrochloride under basic conditions.
The 5′ -dimethylamino and 5′ -dimethylsulfonio compounds
23a,b and 25a-d were prepared by routine methods (Scheme
5). The dimethylamino group was introduced by displacement
o fa5 ′ -chlorine on 8a or 8g
32 with dimethylamine. The
5′ -methylthio compounds 24a,b were treated with methyl
bromide to produce 25a and 25c. Ion exchange was utilized to
prepare the chloride salts 25b and 25d. 8-Methyl-5′ -methylthio
Figure 1. Previously described inhibitors of hAdoMetDC.
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in 8a with sodium thiomethoxide.
Modeling of MeAdoMet in the Active Site of AdoMetDC.
The crystal structures of AdoMetDC complexed with MeAdo-
Met or the inhibitors 3 and 5 have shown that the ligand binds
with the adenine base in the unusual syn conformation.
25 The
active site residues of AdoMetDC with MeAdoMet bound are
shown in Figure 2. However, NMR data, coupled with molecular
modeling studies, suggest that in solution AdoMet assumes an
anti conformation as an energy minimum.
33 A survey of crystal
structures in which AdoMet is bound showed that the substrate
assumes a range of glycosidic torsion angles but that the anti
conformation is preferred.
33 To explain the conformational
preferences and the related energetics of ligand binding to
AdoMetDC, the modeling of MeAdoMet in the active site of
AdoMetDC was done. Because MeAdoMet is tethered to the
active site of AdoMetDC through covalent bonding to the
pyruvoyl group, docking involving positional and orientational
sampling was not performed. Instead, a conformational search
to locate the populated low energy conformations of MeAdoMet
in the AdoMetDC active site was performed using the mixed
Monte Carlo/low mode conformational search method within
the MacroModel program.
34-36 The conformational search
started with MeAdoMet in either the anti or syn conformation,
and in each case the ﬁve lowest energy structures from the
search exhibited a syn conformation for the adenine nucleoside.
A superposition of the modeled structure with the crystal
structure (Figure 2) indicates that the results of the conforma-
tional search match well with those observed crystallographi-
cally. Conformational searches were also done for AdoMet, 5′ -
deoxy-5′ -(dimethylsulfonio)adenosine (MMTA), 3, and 5 binding
to AdoMetDC, and each yielded a syn conformation for the
glycosidic bond (data not shown). The ribose makes key
hydrogen bonds to Glu247 and the adenine base stacks between
Phe7 and Phe223 and also makes hydrogen bonds to the
backbone amide and C-terminal carboxyl group of Glu67. These
interactions together with π-π stacking of the adenine base
with Phe223 and with Phe7 constrain the glycosidic bond to
the syn conformation.
Scheme 1
a
a (a) (CH3)4Sn or (CH3CH2)4Sn, HMDS/dioxane, NMP, (Ph3P)4Pd, 110 °C; (b) CH3NH2, MeOH, 110 °C; (c) C6H5B(OH)2,K 2CO3, (Ph3P)4Pd, 1,2-DME-
H2O (2:1), 90 °C; (d) SOCl2,C H 3CN/pyridine, 0 °C-RT, NH4OH, RT; (e) MsCl, pyridine, 0 °C; (f) 33% CH3NH2, EtOH, RT (9e,f,g)o r9 0°C( 9a-d); (g)
NaOMe/MeOH, RT.
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mutations were made to study the effect of various residues on
the conformation of the bound nucleoside. Conformational
searching with MacroModel employing the AdoMetDC F223A
and F7A single amino acid mutants, with MeAdoMet in the
active site, resulted in a mixture of syn and anti conformations
in the low energy ensemble. With each of the mutations, the
global minimum was an anti conformation of the adenine base,
closely followed by a syn conformation with an energy
difference of ∼2 kJ/mol. The global minimum energy confor-
mation of the ligand bound in the anti conformation in the
F223A mutant exhibits major changes compared to the second
lowest energy conformer which adopts the syn conformation.
In the F223A binding site, the ribose of the global minimum
energy structure is displaced and makes hydrogen bonds to
Glu247 and Cys226 instead of to Glu247 alone (Figure 3A).
This change causes the ligand to twist back upon itself, the
sulfonium stacks over the adenine base, and the adenine base
makes three hydrogen bonds to Ser66. In the F7A binding
site, the ligand assumes a similar conformation as with the
F223A mutant. The Phe223 side chain undergoes a torsional
change to accommodate the conformational change of the
ligand and also stacks with the adenine base (Figure 3B).
The presence of the anti conformation in low energy
structures of the ligand in the enzyme active site where virtual
mutations have been made suggests the importance of the
phenyl groups in maintaining the syn conformation of the
ligand within the wild-type enzyme binding site. However,
since we observed a syn conformation of the nucleoside as
the second lowest energy structure in our conformational
search on the F223A mutant and since the relative energy of
that structure compared to the global minimum (∆E ) 2.5
kJ/mol) is well within the error limit of our calculations, we
were prompted to obtain the crystal structure of the F223A
mutant complexed with MeAdoMet.
Structure of F223A Mutant Complexed with MeAdoMet.
The structure of the F223A mutant is similar to that of the wild
type protein.
22 The human AdoMetDC (hAdoMetDC) protomer
has a four layer R  R fold in which two  -sheets are
sandwiched between two layers of R-helices. The secondary
Scheme 2
a
a (a) CH3(OEt)CdNO(CH2)2Br (ref 28), DMF, DIEA, 50 °C ;( b )1NH 2SO4, RT; (c) CH3(OEt)CdNO(CH2)4Br (ref 29), DMF, DIEA, 50 °C; (d)
2-(methylaminoethanol), RT; (e) N-hydroxyphthalimide, PPh3, DEAD, THF (ref 40), RT; (f)1NH 2SO4,6 0°C.
Scheme 3
a
a (a) Cl(CH2)nCO2Et (n ) 1 or 2), DMF, DIEA, 60 °C; (b) NH3/MeOH, RT; (c)1NH 2SO4, RT; (d) NH2NH2,H 2O, EtOH, reﬂux.
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gesting that the protomer resulted from gene duplication. The
proenzyme consists of 334 amino acid residues, and the enzyme
undergoes autoprocessing to give the R and the   subunits.
22
The autoprocessing reaction yields the active enzyme with the
pyruvoyl cofactor. The pyruvoyl group is located at the end of
the N-terminal  -sheet and the active site involves residues from
both of the  -sheets. The binding site of putrescine, which
activates both the autoprocessing and decarboxylation reactions
of hAdoMetDC, is located well away from the ligand binding
site within the wild-type enzyme. Experimental conditions for
the puriﬁcation of the enzyme included putrescine at sufﬁcient
concentration to ensure high occupancy of the putrescine binding
site. The loops between the residues 1-4, 21-27, 165-173,
288-299, and 329-334 are disordered in the crystal struc-
tures.
Scheme 4
a
a (a) CH3NH(CH2)nNH2 (n ) 1o r2 ) ,R T ;( b )1NH 2SO4, RT; (c) 3-bromopropylphthalimide, DMF, DIEA, 60 °C; (d) NH2NH2,H 2O, reﬂux; (e) 1H-
pyrazole-1-carboxamidine·HCl (ref 30), DMF, DIEA, RT; (f) 3-(methylamino)propionitrile, RT (ref 31); (g) NH2OH·HCl, MeOH, DMF, KOH, RT.
Scheme 5
a
a (a) (CH3)2NH, 2 M solution in MeOH, 90 °C; (b) CH3SNa, DMF, RT; (c) CH3Br, Et2O, HCO2H, HOAc, RT; (d) IRA-400 (Cl-) ion exchange resin.
1392 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 5 McCloskey et al.Figure 2. Comparison in stereoview of the crystal structure of hAdoMetDC complexed with MeAdoMet to that of a structure derived from
the modeling of the complex. The crystal structure has all atoms colored gray. For the model, the active site pyruvoyl group is shown in
magenta and MeAdoMet carbon atoms are shown in green. MeAdoMet makes a Schiff base to the pyruvoyl group. The ribose makes two
hydrogen bonds to Glu247 (shown as red dashed lines). The adenine base stacks between Phe223 and Phe7 in the unusual syn conformation.
The hydrogen bonds between the adenine base and the backbone of Glu67 stabilize the syn conformation. The modeling result agrees well
with the experimentally determined crystal structure.
Figure 3. Comparison in stereoview of modeling of hAdoMetDC F223A and hAdoMetDC F7A mutants, each complexed with MeAdoMet,
with the crystal structure of the F223A mutant with MeAdoMet bound. Global minimum of modeling of MeAdoMet in the active site of the
F223A mutant superposed with the crystal structure (A) and the F7A mutant (B) of hAdoMetDC (see Experimental Section for details). The
crystal structure has all atoms colored gray. The pyruvoyl group is shown in magenta and the ligand carbon atoms are shown in green for
the models. Hydrogen bonds are shown as dashed lines. The adenine base attains an anti conformation in the models. The ribose makes one
hydrogen bond to Glu247 and the other to the backbone carbonyl of Cys226. The adenine base makes three hydrogen bonds to Ser66. In the
F7A model (B), the Phe223 residue changes its conformation to stack with the adenine base of MeAdoMet in the anti conformation.
Adenine C8-Substituted AdoMetDC Inhibitors Journal of Medicinal Chemistry, 2009, Vol. 52, No. 5 1393The crystal structure of hAdoMetDC F223A complexed with
MeAdoMet was solved using molecular replacement. The
difference Fo - Fc density shows that MeAdoMet is covalently
bound to the enzyme, and the nucleoside adopts a clear syn
conformation. As expected, the composite omit map density
shows no density for the Phe223 side chain. The ribose makes
two hydrogen bonds to Glu247, which anchor the ligand, and
the base is held in syn conformation by stacking interactions
with Phe7 and hydrogen bonds between the adenine and Glu67.
One molecule of putrescine per monomer is present in the
expected putrescine binding site. A superposition of the F223A/
MeAdoMet structure and the wild type structure with MeAdoM-
et shows that there is no appreciable change in the position or
conformation of the ligand (Figure 3A). The loops disordered
in the mutant are also disordered in the wild type protein.
Biochemical Analysis of Potential Inhibitors of hAdoMetDC.
The demonstrated importance of the syn conformation of the
adenine base of the AdoMet substrate for binding in the active
site of the enzyme led us to explore whether this could be
exploited in designing better hAdoMetDC inhibitors. It is known
that 8-substitution on adenine rings causes the nucleotide to
favor a syn conformation in solution.
26,27,37,38 It was thought
that structural analogues of AdoMet that preferred the syn
conformation in solution would lead to improved hAdoMetDC
inhibition. Modeling of the active site had indicated that there
was sufﬁcient room to accommodate even rather large substit-
uents at C8 of adenine. Several series of AdoMet structural
analogues were synthesized with substituents ranging from a
methyl group to a phenyl group at the 8-position of adenine.
Each of these compounds was then assayed for its ability to
inhibit hAdoMetDC and IC50 values for the inhibition were
determined (Table 1).
The inhibitors tested fall into four groups as described in
the “Chemical Synthesis” section. One group (12a-c, 14a-f,
5) has an aminooxyalkyl side chain at C-5′ , which can form
a Schiff base with the pyruvate of AdoMetDC
20,39-41
Compounds of this group were potent inhibitors, with a
4-aminooxybutyl group being slightly superior to a 2-ami-
nooxyethyl addition. A second group of compounds
(17d,e,f,j,k,l,m) had an amide or a hydrazide side chain at
C-5′ , and a third group of inhibitors (18a,b,d,e,f; 19a,b,c,d;
21c,d) had an aminoalkylamino side chain at C-5′ . Also
related to the third group by the synthetic method are 22a
and 22c, which, respectively, have a guanidine and an
amidoxime at the end of the C-5′ side chain. The compounds
of groups 2 and 3 were less potent (particularly those with
the aminoalkylamino, guanidine, or amidoxime side chain)
but are more likely to be stable under in vivo conditions.
The ﬁnal group of compounds consisted of 5′ -dimethylamino
(23a,b)o r5 ′ -dimethylsulfonio (25b,d) compounds. Com-
pound 25d has been previously reported to be an AdoMetDC
inhibitor with a Ki in the µM range.
32 As shown in Table 1,
the replacement of sulfur by nitrogen slightly improves the
AdoMetDC inhibition.
Within each of these groups, there was a consistent improve-
ment of inhibitory activity when an 8-methyl substituent was
added to the adenine ring. The reduction in the IC50 value varied
from 3.4-fold for compound 14d to 15-17-fold for compounds
23a and 17d. There was an 8-fold increase in potency when an
adenine 8-methyl substituent was added to compound 5, forming
compound 12a. This is consistent with the concept that the
8-methyl substitution on adenine biases the corresponding
nucleoside toward the syn conformation and that this is the form
that is bound at the active site. An adenine 8-hydroxy substituent
resulted in slightly increased potency compared to no substituent
but was not as effective as the 8-methyl substituent (compare
14c to 14d and 14f). Larger 8-substitutions did not improve
the effectiveness. An 8-phenyl addition to compounds 5, 14f,
and 18d abolished the inhibitory activity. Smaller additions such
as 8-ethyl (compare 14d and 14e, 17d and 17e, and 21c and
21d) or 8-methylamino (compare 12a and 12b and 21c and 18a)
were tolerated but were worse than 8-methyl.
Crystal Structures of hAdoMetDC Complexes. The crystal
structure of native hAdoMetDC with 12a was solved using
molecular replacement (Figure 4A). As noted above, 12a is
structurally similar to the previously studied inhibitor 5 except
that it has a methyl substitution at the 8-position on the adenine
base. The electron density indicates that the amino terminus of
12a forms a Schiff base with the pyruvoyl group of the enzyme.
The adenine base of 12a adopts a syn conformation in the crystal
structure as expected. There is one molecule of putrescine bound
in the putrescine binding site.
The crystal structure of native hAdoMetDC with 14e was
solved using molecular replacement (Figure 4B). Compound
14e is similar to 5 except for an ethyl substituent on the
8-position of the adenine base and two extra carbon atoms
between the tertiary nitrogen (near ribose) and the terminal
nitrogen. The presence of a three-carbon linker between the
ribose and the amino terminus makes this ligand interesting to
study. The electron density maps show no density for Schiff
base formation between the pyruvoyl group and the amino
terminus of the ligand. There is no density for the terminal three
atoms of the ligand, but there is good density for the rest of the
ligand. The position of the last three atoms was obtained by
Table 1. Inhibition of hAdoMetDC
a
compd IC50
12a 7n M
12b 86 nM
12c <5% inhibition at 100 µM
14a 49 nM
14b <5% inhibition at 100 µM
14c 11 nM
14d 5n M
14e 15 nM
14f 18 nM
5 55 nM
17d 400 nM
17e 4 µM
17f <5% inhibition at 100 µM
17j 7 µM
17k 170 nM
17l 1.5 µM
17m 31 µM
18a 440 µM
18b <5% inhibition at 100 µM
18d 500 µM
18e <5% inhibition at 100 µM
18f 88 µM
19a <5% inhibition at 100 µM
19b <5% inhibition at 100 µM
19c <5% inhibition at 100 µM
19d <5% inhibition at 100 µM
21c 70 µM
21d 420 µM
22a <5% inhibition at 100 µM
22c 157 µM
23a 600 nM
23b 9 µM
25b 3 µM
25d 15 µM
a Each of the potential inhibitors was assayed for the ability to inhibit
hAdoMetDC. At least ﬁve concentrations of each compound were used
and IC50 values were calculated from curve ﬁts to plots of inhibitor
concentration versus % inhibition of hAdoMetDC.
1394 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 5 McCloskey et al.modeling them to an energetically favorable conformation using
molecular modeling. The density around the pyruvoyl group
ﬁts it well and does not show any evidence of formation of a
Schiff base. The ribose makes the critical hydrogen bonds to
Glu247 and anchors the ligand. The nucleoside is held in the
syn conformation and is stabilized by π-π stacking. The density
of the ethyl substituent on the base is well deﬁned indicating
that the substituent is not disordered.
The crystal structures of hAdoMetDC with 17d (Figure 4C),
17f (Figure 4D), and 21c (Figure 4E) were also determined by
molecular replacement. The three ligands have 8-methyl sub-
stituents; the ﬁrst two have carboxamide end groups at the 5′ -
tail, while the third ligand has an amino group in this position.
All three ligands showed clear electron density and all three
ligands bound in the syn conformation.
Discussion
The active site of AdoMetDC contains a bound pyruvoyl
cofactor. The interactions of various ligands at the active site
were elucidated previously from the crystal structures obtained
from complexes of the enzyme with the inhibitors 3 (PDB 1I79),
5 (PDB 1I72), MeAdoMet (PDB 1I7B), 1 (PDB 1I7C), and 2
Figure 4. Complexes of hAdoMetDC with inhibitors having 8-substitutions. The carbon atoms of the inhibitor are shown in green and the pyruvoyl
group is shown in magenta. Water molecules are shown as red spheres and hydrogen bonds are shown as dashed lines. (A) Complex with 12a. The
ligand makes a Schiff base linkage to the active site pyruvoyl group. (B) Complex with 14e. There is no evidence from the electron density for the
formation of a Schiff base, and there is no density for the terminal three atoms of the ligand. The position of the terminal three atoms is determined
by modeling. (C) Complex with 17d. The carboxamide terminus of the ligand makes hydrogen bonds to Leu65 and Ser229. (D) Complex with 17f.
The carboxamide terminus of the ligand makes water mediated hydrogen bonds to Glu11 and Gly9. (E) Complex with 21c. The amino terminus
of the ligand makes water mediated hydrogen bonds to Glu11 and Gly9. The inhibitors 17d, 17f, and 21c do not make a Schiff base to the enzyme
and are hence competitive inhibitors. The adenine base of all the inhibitors attains a syn conformation.
Adenine C8-Substituted AdoMetDC Inhibitors Journal of Medicinal Chemistry, 2009, Vol. 52, No. 5 1395(PDB 1I7M).
25 The crystal structure of MeAdoMet covalently
bound to the enzyme most closely approximates the substrate
AdoMet in the active site. The crystal structure shows key
interactions of MeAdoMet with the enzyme including: (1)
hydrogen bonding of the ribose oxygens with Glu247, (2) π-π
stacking interactions of the adenine ring with Phe223 and Phe7,
(3) hydrogen bonding of the 6-amino substituent of the adenine
ring with Glu67, the C-terminal residue of the  -chain, and (4)
hydrogen bonding of N-1 of the adenine ring with the backbone
amide group of Glu67 (Figure 2A). Similar interactions are also
present in the structures of 3 and 5 complexed with hAdoMet-
DC. The glycosidic angle for the adenine base in the structures
ranges from 128° to 139°, which demonstrates a preference for
the syn conformation of the nucleoside when bound to the active
site. Crystal structures of 1 and 2 with the enzyme show that
they stack between the two phenyl rings and make hydrogen
bonds to Glu247.
The molecular modeling of MeAdoMet in the active site
of hAdoMetDC was performed by using mixed Monte Carlo/
low mode conformational searching as described above. The
glycosidic torsional angle was free to rotate during the
conformational search, which would allow a wide range of
rotamers that are compatible with the steric constraints of
the active site before energy minimization. The low energy
structures show that the adenine-derived nucleosides prefer
the syn conformation in the active site of hAdoMetDC.
Markham et al. have studied the conformational preferences
of AdoMet in solution and in vacuo.
33 These studies based
on 1H NMR and calculations based on NMR constraints have
shown that AdoMet prefers an anti conformation in solution
and a syn conformation in vacuo. In solution, the energy
difference between the anti and the corresponding syn
conformation, which includes steric, electrostatic, and the
solvation contributions, is around -34 kJ/mol. However,
these calculations were based on molecular mechanics
without polarization effects and it is likely that the energy
difference is much less negative. Our crystal structures and
modeling results show that hAdoMetDC binds ligands in the
syn conformation and that the energy difference is overcome
by hydrogen bonding and π-π interactions with Phe7 and
Phe233. Typical π-π interactions of parallel geometry
account for a stabilization of 8-12 kJ/mol,
42 suggesting that
other factors may be involved.
The roles of Phe223 and Phe7 in AdoMetDC were studied
previously through crystal structures and kinetic experiments.
25
Kinetic data from reaction of hAdoMetDC F223A and F7A
mutants with the substrate AdoMet have shown that there is a
45-fold reduction of efﬁciency (kcat/km) for the F7A mutant and
a 1400-fold decrease with the F223A mutant. In addition, 1 and
2 show a signiﬁcant increase in the IC50 values for both the
F7A and F233A mutants when compared to the wild-type
enzyme, with decrease in binding greater for F223A than for
F7A. Therefore, we chose to investigate the structural and
conformational properties of MeAdoMet in the active site of
the F223A mutant.
Our conformational searches with virtual mutations were done
to understand the roles of Phe223 and Phe7 in stabilizing the
syn conformation. In contrast to calculations done with the wild
type enzyme structure, in which only the syn conformation was
observed for the ensemble of lowest energy structures, the global
minimum from both the mutations has the base in an anti
conformation and the next higher energy structure has the base
in a syn conformation. The difference in the energy between
these conformations is about 2 kJ/mol, which we estimate to
be within the error limit of our molecular mechanics based
calculations. The energy difference between the syn and anti
conformation of both structures is low, and based on the X-ray
structure of hAdoMetDC F223A with bound MeAdoMet, the
enzyme binds the ligands in the syn conformation, suggesting
that π-π interactions with Phe7 are sufﬁcient to maintain the
syn conformation. Thus, although the modeling studies were
incapable of accurately predicting that the syn conformation of
the nucleoside would be maintained in the F223A mutant, it
was possible to infer from these studies that the binding afﬁnity
of the nucleoside for the enzyme would be diminished.
Our attempts to exploit the requirement by AdoMetDC for a
ligand with a syn conformation were successful, as demonstrated
by the 8- to 18-fold improvement in inhibition when a methyl
group is attached to C-8. However, the larger substituents that
we tested provided no beneﬁt over the unsubstituted parent
compounds. In fact, the 8-phenyl substituent rendered the
compounds much less potent than the unsubstituted analogue.
Modeling studies of the active site had indicated that there
should be sufﬁcient space to accommodate the larger groups
with the adenine in the syn conformation. A more detailed look
at the area occupied by adenine C-8 substituents has indicated
that this area is near the solvent interface. On the basis of our
biochemical results, although large 8-substituents were structur-
ally compatible with the active site, the penalty of incompletely
burying a large hydrophobic group within a hydrophobic cavity
is apparently greater than the gain from favoring the syn
conformation. We are now exploring the effect of more
hydrophilic C-8 adenine substituents that should be more
compatible with proximity to the solvent. Such substituents may
be useful in maintaining the inhibitory potency associated with
the syn structure while still allowing species speciﬁc binding.
Structures of many of the AdoMet analogues bound to
AdoMetDC have shown that they inhibit the enzyme through
Schiff base formation with the pyruvoyl group of the enzyme.
The linker length between the tertiary ammonium/sulfur and
the terminal nitrogen of those inhibitors is typically 3-4 atoms,
which makes the formation of a Schiff base geometrically and
sterically feasible. Compound 14e has a linker length of ﬁve
atoms. The electron density map for the complex of 14e shows
a break in the density after the pyruvoyl group, suggesting that
there is no Schiff base formation. There is good density for the
ligand except at the three terminal atoms, which are disordered
and have no density. The positions of the last three atoms were
ﬁxed in an energetically favorable conformation using computer
modeling. The ﬁve atoms of the linker region appear to cause
a sterically unfavorable orientation for formation of the Schiff
base. The ligand is still held rigidly in the active site by hydrogen
bonds to Glu247 and the π-π stacking interactions with Phe7
and Phe223, and thus little movement is allowed to accom-
modate Schiff base formation for the longer linker region. Even
though compound 14e is not covalently attached to the pyruvoyl
group, its potency is better than 5 and nearly as good as
compound 12a.
Conclusion
Previous structural studies showed that AdoMet binds to the
active site of hAdoMetDC in the syn conformation, suggesting
that adenosine analogues favoring the syn conformation in
solution might be more potent inhibitors than corresponding
analogues favoring the lower energy anti conformation. 8-Sub-
stituted nucleoside analogues favor the syn conformation
because of unfavorable interactions in the anti conformation
between a bulky 8-substituent and ribose. We used computer
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to hAdoMetDC and synthesized and assayed the most promising
candidates. We also determined crystal structures of several
compounds bound to hAdoMetDC to validate the predictions;
the structures conﬁrmed that the 8-substituted analogues bound
in the syn conformation and retained the previously identiﬁed
features of AdoMet binding, namely, purine stacking between
Phe7 and Phe223, and hydrogen bonding between the ribose
hydroxyl groups and Glu247. A group of adenosine analogues
was generated by varying the size and nature of the both the
8-substituent and the 5′ -modiﬁcation. In general, 8-substituted
analogues bound with a potency of 8- to 18-fold higher
compared to the corresponding compound with a hydrogen atom
at the 8-position; however, 8-substituents larger than methyl
often showed lower potency than the corresponding 8-H
compound. The observation results from excessive solvent
exposure for large 8-substituents. Computer modeling and X-ray
crystallography were also used to understand the preference for
the syn conformation. Modeling studies suggested an important
role for the two active site phenylalanine residues in addition
to Glu247; however, the crystal structure of the F223A mutant
hAdoMetDC showed that AdoMet still binds in the syn
conformation, suggesting that other factors that favor the syn
conformation remain to be identiﬁed.
Experimental Section
Protein Production. For crystallography of wild type and F223A
mutant hAdoMetDC, plasmids in the pQE30 vector in E. coli were
produced as described previously.
25 This construct replaces the
N-terminal methionine with MRGS(H)6GS- for puriﬁcation by
immobilized metal afﬁnity chromatography. A different plasmid
also based on the pQE30 vector was used for the production of
protein for the hAdoMetDC enzyme assays. In this plasmid, the
(H)6 tag was located at the carboxyl end replacing the terminal
-QQQQQS. The position of the (H)6 tag did not alter the activity
of the puriﬁed enzyme.
The wild type hAdoMetDC was puriﬁed based on the protocol
described by Ekstrom et al.
22 The plasmid encoding the enzyme is
in the pQE30 vector and was transformed into JM109 strain E.
coli cells. The cells were grown as an overnight culture in LB media
at 37 °C and then introduced into larger cell cultures with both of
the cultures containing 100 mg/mL ampicillin. The cells were grown
until they reached an OD600 of 0.6 and then were induced with 100
mg/L isopropyl  -D-thiogalactopyranoside (IPTG). The cells were
allowed to grow overnight at 15 °C and were then harvested by
centrifugation, washed using a wash buffer that contained 20 mM
Na2HPO4, pH 7.0, 500 mM NaCl, 2.5 mM putrescine, 0.02% Brij-
35 and 10 mM imidazole, and stored at -80 °C. The frozen cell
pellet was thawed, suspended in the wash buffer, and lysed using
a French press at 1500 psi. The cellular debris and the lysate were
separated by centrifugation at 12000g. Talon metal afﬁnity resin
was equilibrated with the wash buffer, and then the lysate and the
resin were gently spun together for 1.5 h. The resin was loaded
onto a column and washed with a volume of wash buffer equivalent
to 15-20 times the column volume. Next, the column was washed
in the same manner with wash buffer containing 25 mM imidazole.
The protein was then eluted with buffer containing 100-200 mM
imidazole. The eluted protein solution was concentrated to around
10 mL and passed through a Sephadex G-75 column pre-
equilibrated with 10 mM N-(2-hydroxyethyl)piperazine-N′ -2-
ethanesulfonic acid (HEPES), pH 7.5, 2.5 mM putrescine, 5 mM
dithiothreitol (DTT), 0.1 mM ethylenediaminetetraacetic acid,
0.02% Brij-35, and 300 mM NaCl. The buffer was run through the
column, and the fractions containing the protein were identiﬁed by
UV absorbance at 280 nm. The protein was concentrated to ∼10
mg/mL and stored at -80 °C. The puriﬁcation of the F223A mutant
was similar to that of the native enzyme.
Structure Determination. The protein was thawed on ice and
buffer exchanged to 10 mM HEPES, pH 7.5, 200 mM NaCl and 1
mM DTT using Bio-Rad buffer exchange chromatography columns
(Bio-Rad Laboratories, Hercules, CA 94547). The wild type protein
was incubated with a 4-6 M excess of inhibitor for 24 h prior to
crystallization. The F223A mutant was diluted to ∼6 mg/mL and
incubated with a 4-6 M excess of MeAdoMet for 24 h prior to
crystallization. Crystals of both the native and the mutant complexes
were grown using the hanging drop method at 22 °Ci n1 3 -16%
PEG 8000, 100 mM Tris, pH 8.0-9.0, and 10 mM DTT. Crystals
appeared overnight and were stable for 1-2 weeks.
The data for the 12a complex were collected at a home source
with a Rigaku R-AxisIV++ image plate detector using Cu KR
radiation from a Rigaku RU-300 rotating anode generator. The data
for the 14e complex were collected at NE-CAT beamline 8-BM at
the Advanced Photon Source (APS) using a ADSC Q315 detector.
Data for the 17f complex were collected at NE-CAT beamline 24-
ID-C using an ADSC Q315 detector. The data for the AdoMetDC
F223A mutant with MeAdoMet and the complexes with 17d and
21c were collected at the F2, A1, and A1 stations of CHESS,
respectively, using an ADSC Q210 detector. The diffraction quality
of the crystals strongly depended on cryoprotection conditions. The
crystals were sequentially transferred to a solution containing the
well solution with 2, 5, 8, 15, and 18% glycerol with 1-2 min
equilibration between each step. The data for all of the complexes
were indexed, integrated, and scaled using the HKL2000
43 program
suite. The data collection statistics are summarized in Table 2.
The structures of all of the complexes were determined by
molecular replacement using the structure of native AdoMetDC
with MeAdoMet bound (PDB 1I7B) as the search model, and the
CNS program suite.
44 The model building was done using the
program O
45 or Coot.
46 The conformations of the ligand molecules
were determined using difference Fo - Fc and composite omit maps.
The parameters and the topology ﬁles for the ligands were generated
using the HIC-Up server.
47 The difference maps also showed
Table 2. Data Collection Statistics for hAdoMetDC Complexes
F223A + MeAdoMet 12a 14e 17d 17f 21c
wavelength 0.9795 1.5418 0.9795 0.9790 0.9792 0.9771
space group (Å) C2 C2 C2 C2 C2 C2
a (Å) 95.98 96.78 94.43 99.82 99.65 100.08
b (Å) 44.25 44.46 50.04 50.95 50.75 50.75
c (Å) 70.83 70.55 70.41 68.98 68.90 69.04
  104.52 104.17 105.34 105.52 105.34 105.56
resolution (Å) 2.62 2.43 1.83 1.84 1.91 1.86
total/unique reﬂections 23532/8160 26010/10403 83134/26894 89749/28243 97188/25449 77769/27505
redundancy 2.9(2.6)
a 2.5 (1.9) 3.1(3.1) 3.2(2.6) 3.8(2.6) 2.8(2.5)
% complete 92.9(91.2) 93.6(86.8) 95.6(95.5) 97.6(94.1) 98.8(91.0) 98.7(96.8)
I/σ 13.3(2.0) 10.9(2.9) 13.5(2.7) 17.4(8.0) 16.6(3.9) 14.2(2.2)
Rsym
b 7.7(45.2) 9.0(33.8) 7.2(54.8) 6.0(14.0) 7.6(25.0) 7.1(39.1)
Matthews no. 1.90 1.92 2.09 2.21 2.19 2.21
solvent content (%) 34.1 34.8 39.7 43.2 42.9 43.2
a Values in parenthesis are for the highest resolution shell.
b Rsym ) ∑∑ i|Ii - 〈 I〉 |/∑〈 I〉 , where 〈 I〉 is the mean intensity of the N reﬂections with intensities
Ii and common indices h,k,l.
Adenine C8-Substituted AdoMetDC Inhibitors Journal of Medicinal Chemistry, 2009, Vol. 52, No. 5 1397density for a molecule of putrescine bound in all of the structures.
The reﬁnement statistics of the complexes are given in Table 3.
Molecular Modeling. Determination of the conformational
preference of ligands in the active site of AdoMetDC was carried
out with Macromodel version 7.2,
36 available from Schro ¨dinger,
LLC. To make the computational studies tractable, the protein was
truncated to a shell of atoms that included any residue that contained
an atom within 20.0 Å of MeAdoMet located in the active site of
AdoMetDC (from PDB 1I7B) and was used as the starting model
for conformational searching/energy minimization. Removal of
water molecules from this “docking shell” was followed by
appropriate hydrogen treatment using Schro ¨dinger’s protein prepa-
ration utility that aids in the generation of appropriate ionic states
and histidine tautomers for active site amino acids and minimizes
the protein’s potential energy gradient through a series of con-
strained energy minimizations. For the conformational searches,
the appropriate ligand was added to the active site and, where
appropriate, the covalent bond between the amino terminus of the
ligand and the pyruvoyl group was formed.
The resulting structures were subjected to 50,000 mixed Monte
Carlo MCMM/low mode conformational search steps,
34,35 allowing
residues withina5Åshell surrounding the active site to freely
move during each Monte Carlo/low mode step and subsequent
energy minimization step of the search. All other protein atoms
were constrained to their starting position. Residues His5, Glu67,
Cys226, and Glu247 were also constrained to their starting position.
The energy minimization step was considered to have converged
when the energy gradient was less than 0.05 kJ/mol. The AMBER*
force ﬁeld,
48,49 with a distance dependent dielectric “constant”
further attenuated by a factor of 4, was employed for the
calculations, and the energy minimizations relied upon the TNCG
minimization technique.
50 The global minimum and low energy
ensemble of structures within 15 kJ/mol of the global minimum
(after convergence) were further reﬁned by energy minimization
until a gradient less than 0.01 kJ/mol was obtained with just the
ligand allowed to move during this subsequent energy minimization
procedure. All protein atoms during this process were constrained
to their starting position. The jobs were run with the nucleoside
starting in both the syn and anti conformations for completeness.
The AMBER* parameters for the sulfonium ion were adapted from
the work done by Markham et al.
33
The modeling of the terminal three atoms of 14e was done using
conformational searching with Macromodel version 7.2 as described
above. Because the position of the rest of the ligand and the protein
was determined to high accuracy by ﬁtting to the electron density
determined by X-ray diffraction, all of the protein and the ligand
atoms except the last three non-hydrogen atoms and their attached
hydrogens were ﬁxed during the conformational search. Torsional
rotation was allowed around the last two bonds of the C-5′ extension
during the conformational search. A visual survey of the ﬁve lowest
energy structures, which spanned an energy range of 6.5 kJ/mol,
showed that they were similar and the global minimum of the search
was utilized to obtain the coordinates of the disordered terminal
atoms of 14e.
AdoMetDC Activity and Inhibition. AdoMetDC was assayed
by measuring the release of 14CO2 from S-adenosyl-L-[carboxy-
14C]methionine (Amersham Pharmacia Biotech, ∼60 mCi/mmol).
51
Assay of 30 ng of C-terminal his-tagged AdoMetDC under these
conditions results in ∼7000 cpm with a background of 30 and an
activity of ∼1.5 pmol/min/ng protein. For determination of the
abilities of compounds to inhibit AdoMetDC, the enzyme activity
was determined in the presence of no inhibitor and at least ﬁve
concentrations of each potential inhibitor. The enzyme concentation
was 1 nM. The IC50 values were determined from curve ﬁtting to
plots of the inhibitor concentration versus the % inhibition of
AdoMetDC.
Target Synthesis. TLC analysis was performed on Analtech
precoated (250 µm) silica gel GF plates. Melting points were
determined on a Mel-Temp apparatus and are uncorrected. Puriﬁca-
tions by ﬂash chromatography were carried out on Merck silica
gel (230-400 mesh). Evaporations were performed with a rotary
evaporator, higher boiling solvents (dimethylformamide (DMF),
pyridine) were removed in vacuo (<1 mm, bath to 35 °C). Products
were dried in vacuo (<1 mm) at 22-25 °C over P2O5. The mass
spectral data were obtained with a Varian-MAT 311A mass
spectrometer in the fast atom bombardment (FAB) mode or with a
Bruker BIOTOF II by electrospray ionization (ESI). 1H NMR
spectra were recorded on a Nicolet NT-300 NB spectrometer
operating at 300.635 MHz. Chemical shifts in CDCl3 and Me2SO-
d6 are expressed in parts per million downﬁeld from tetramethyl-
silane (TMS) and in D2O chemical shifts are expressed in parts
per million downﬁeld from sodium 3-(trimethylsilyl)propionate-
2,2,3.3-d4 (TMSP). Chemical shifts (δ) listed for multiplets were
measured from the approximate centers, and relative integrals of
peak areas agreed with those expected for the assigned structures.
UV absorption spectra were determined on a Perkin-Elmer Lambda
Table 3. Reﬁnement Statistics for AdoMetDC Complexes
F223A + MeAdoMet 12a 14e 17d 17f 21c
resolution (Å) 2.62 2.43 1.83 1.84 1.91 1.86
R factor
a 0.203 0.199 0.208 0.204 0.197 0.200
R-free
b 0.280 0.247 0.231 0.237 0.208 0.232
no. of non-H atoms
protein 2473 2419 2381 2489 2454 2470
ligand 28 25 28 26 25 25
water 79 73 137 222 212 217
B factors
protein (Å2) 41.3 31.5 29.6 26.8 28.2 32.4
ligand (Å2) 63.4 42.1 32.3 26.0 43.9 39.9
putrescine (Å2) 32.4 27.9 40.0 22.4 24.7 29.8
rms deviations
bonds (Å) 0.010 0.011 0.007 0.006 0.012 0.008
angles (deg) 1.4 1.4 1.3 1.3 1.4 1.3
dihedrals (deg) 24.9 25.2 25.3 25.3 25.8 25.2
Ramachandran plot
most favored region (%) 84.2 89.3 91.4 91.8 92.1 92.5
additional favored region (%) 14.7 9.5 7.8 7.8 7.5 7.5
generously allowed region (%) 0.8 0.8 0.4 0.4 0.4 0.0
disallowed region (%) 0.4 0.4 0.4 0.0 0.0 0.0
a R factor ) ∑ hkl|Fobs| - k|Fcal|/∑ hkl|Fobs|, where Fobs and Fcal are observed and calculated structure factors, respectively.
b In R-free, the sum is extended
over a subset of reﬂections that were excluded from all stages of reﬁnement.
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and diluting 10-fold with 0.1 N HCl, pH 7 buffer, or 0.1 N NaOH.
Numbers in parentheses are extinction coefﬁcients (ε × 10-3).
Microanalyses were performed by Atlantic Microlab, Inc. (Atlanta,
GA) or the Spectroscopic and Analytical Department of Southern
Research Institute. Analytical results indicated by element symbols
were within (0.4% of the theoretical values, and where solvents
are indicated in the formula, their presence was conﬁrmed by 1H
NMR.
5′ -Chloro-5′ -deoxy-8-methyladenosine (8a). To a stirred sus-
pension of 7a
38 (892 mg, 3.17 mmol) in anhydrous pyridine (501
mg, 0.51 mL, 6.33 mmol) and CH3CN (2.5 mL) cooled in an ice
bath was slowly added SOCl2 (1.88 g, 1.15 mL, 15.80 mmol).
Stirring was continued at 0-5 °C for 3-4 h, with subsequent
warming to ambient temperature overnight. The resulting suspension
was concentrated in vacuo. To this reaction mixture was added
methanol (20 mL), water (2 mL), and NH4OH (4 mL), followed
by stirring for 0.5 h at room temperature. The reaction mixture
was concentrated to dryness. The compound was dissolved in
MeOH, silica gel (3 g) was added and then solvent was removed.
The mixture on silica gel was poured onto a column ﬁlled with
silica gel and eluted with chloroform:methanol (7:1) to yield 661
mg (70%). MS m/z 300 (M + H)+. 1H NMR (DMSO-d6) δ 8.09
(bs, 1H, H-2), 7.15 (bs, 2H, 6-NH2), 5.81 (d, 1H, H-1′ , J1′ ,2′ ) 5.7
Hz), 5.49 (d, 1H, 2′ -OH, J2′ -2′ OH ) 6.1 Hz), 5.45 (d, 1H, 3′ -OH,
J3′ -3′ OH ) 5.3 Hz), 5.13 (ddd, 1H, H-2′ , J1′ ,2′ ) 5.7 Hz, J2′ ,3′ ) 4.8
Hz, J2′ -2′ OH ) 6.1 Hz), 4.31 (ddd, 1H, H-3′ , J2′ ,3′ ) 4.8 Hz, J3′ ,4′ )
4.0 Hz, J3′ -3′ OH ) 5.3 Hz), 4.03-4.10 (bm, 1H, H-4′ ), 3.93-3.99
(m, 1H, 5′ -CH2), 3.82-3.88 (m, 1H, 5′ -CH2), 2.55 (s, 3H, 8-CH3).
5′ -Chloro-5′ -deoxy-8-ethyladenosine (8b). The procedure was
the same as reported above for 8a using 7b
38 (1.28 g, 4.33 mmol),
pyridine (685 mg, 0.70 mL, 8.65 mmol), CH3CN (10 mL), and
SOCl2 (2.57 g, 1.58 mL, 21.60 mmol): yield 498 mg (37%). MS
m/z 314 (M + H)+. 1H NMR (DMSO-d6) δ 8.09 (bs, 1H, H-2),
7.14 (bs, 2H, 6-NH2), 5.80 (d, 1H, H-1′ , J1′ ,2′ ) 5.7 Hz), 5.48 (d,
1H, 2′ -OH, J2′ -2′ OH ) 6.1 Hz), 5.45 (d, 1H, 3′ -OH, J3′ -3′ OH ) 5.4
Hz), 5.20 (ddd, 1H, H-2′ , J1′ ,2′ ) 5.7 Hz, J2′ ,3′ ) 4.6 Hz, J2′ -2′ OH )
6.1 Hz), 4.30-4.37 (bm, 1H, H-3′ ), 4.03-4.10 (bm, 1H, H-4′ ),
3.94-4.0 (m, 1H, 5′ -CH2), 3.83-3.89 (m, 1H, 5′ -CH2), 2.89 (q,
2H, 8-CH2CH3), 1.31 (t, 3H, 8-CH2CH3).
5′ -Chloro-5′ -deoxy-8-(methylamino)adenosine (8c). Compound
8c was prepared by the same procedure as described for the
preparation of 8a using 7c
39,41 (2.9 g, 9.78 mmol), pyridine (1.54
g, 1.57 mL, 19.46 mmol), CH3CN (5 mL), and SOCl2 (5.82 g, 3.56
mL, 48.91 mmol): yield 1.95 g (63%). MS m/z 315 (M + H)+. 1H
NMR (DMSO-d6) δ 7.91 (bs, 1H, H-2),), 6.78 (q, 1H, 8CH3-NH),
6.50 (bs, 2H, 6-NH2), 5.70 (d, 1H, H-1′ , J1′ ,2′ ) 5.0 Hz), 5.41 (d,
1H, 2′ -OH, J2′ -2′ OH ) 5.6 Hz), 5.32 (d, 1H, 3′ -OH, J3′ -3′ OH ) 5.3
Hz), 5.18 (ddd, 1H, H-2′ , J1′ ,2′ ) 5.0 Hz, J2′ ,3′ ) 5.4 Hz, J2′ -2′ OH )
5.6 Hz), 4.33 (ddd, 1H, H-3′ , J2′ ,3′ ) 5.4 Hz, J3′ ,4′ ) 4.4 Hz, J3′ -3′ OH
) 5.3 Hz),), 3.91-4.02 (bm, 2H, H-4′ ,5 ′ -CH2), 3.76-3.82 (m,
1H, 5′ -CH2), 2.88 (d, 3H, 8NH-CH3, J ) 4.5 Hz).
5′ -Chloro-5′ -deoxy-8-phenyladenosine (8d). The procedure
described for 8a was used to prepare 8d from 7d
40(4.5 g, 13.10
mmol), pyridine (2.07 g, 2.12 mL, 26.2 mmol), CH3CN (6 mL),
and SOCl2 (7.79 g, 4.78 mL, 65.47 mmol): yield 2.21 g (47%).
MS m/z 362 (M + H)+. 1H NMR (DMSO-d6) δ 8.20 (s, 1H, H-2),
7.71-7.76 (m, 2H, 8-phenyl o-H’s), 7.59-7.64 (m, 3H, 8-phenyl
m- and p-H’s), 7.40 (bs, 2H, 6-NH2), 5.75 (d, 1H, H-1′ , J1′ ,2′ ) 6.0
Hz), 5.52 (d, 1H, 2′ -OH, J2′ -2′ OH ) 5.6 Hz), 5.39-5.44 (m, 2H,
H-2′ ,3 ′ -OH), 4.33 (bs, 1H, H-3′ ), 3.98-4.06 (bm, 2H, H-4′ ,5 ′ -
CH2), 3.88-3.94 (m, 2H, 5′ -CH2).
5′ -Deoxy-5′ -methylamino-8-methyladenosine (9a). A mixture of
8a (660 mg, 2.20 mmol) in 33% methylamine/ethanol solution (30
mL) in a steel bomb was heated for two days at 90 °C. The reaction
mixture was concentrated to dryness and puriﬁed by column
chromatography (elution with 4:1:0.3 chloroform:methanol:NH4OH
to yield 294 mg (45%). MS m/z 295 (M + H)+. 1H NMR (DMSO-
d6) δ 8.08 (bs, 1H, H-2), 7.14 (bs, 2H, 6-NH2), 5.72 (d, 1H, H-1′ ,
J1′ ,2′ ) 6.5 Hz), 5.30 (d, 1H, 2′ -OH, J2′ -2′ OH ) 6.3 Hz), 5.17 (bd,
1H, 3′ -OH, J3′ -3′ OH ) 3.5 Hz), 5.01 (ddd, 1H, H-2′ , J1′ ,2′ ) 6.5 Hz,
J2′ ,3′ ) 5.5 Hz, J2′ -2′ OH ) 6.3 Hz), 4.16 (bs, 1H, H-3′ ), 3.96-4.0
(m, 1H, H-4′ ), 2.64-2.77 (bm, 2H, 5′ -CH2), 2.53 (s, 3H, 8-CH3),
2.29 (s, 3H, 5′ NH-CH3).
5′ -Deoxy-5′ -methylamino-8-ethyladenosine (9b). The procedure
was the same as reported above for 9a using 8b (1.00 g, 3.18 mmol)
and 33% methylamine/ethanol solution (30 mL). After column
chromatography (elution with 5:1:0.3 chloroform:methanol:
NH4OH), a yellow glassy solid was obtained: 498 mg (50%). MS
m/z 309 (M + H)+. 1H NMR (DMSO-d6) δ 8.08 (bs, 1H, H-2),
7.13 (bs, 2H, 6-NH2), 5.70 (d, 1H, H-1′ , J1′ ,2′ ) 6.6 Hz), 5.30 (d,
1H, 2′ -OH, J2′ -2′ OH ) 6.4 Hz), 5.16 (d, 1H, 3′ -OH, J3′ -3′ OH ) 4.5
Hz), 5.08 (ddd, 1H, H-2′ , J1′ ,2′ ) 6.6 Hz, J2′ ,3′ ) 5.4 Hz, J2′ -2′ OH )
6.4 Hz), 4.14-4.18 (m, 1H, H-3′ ), 3.96-4.0 (m, 1H, H-4′ ), 2.88
(q, 2H, 8-CH2CH3), 2.64-2.78 (m, 2H, 5′ -CH2), 2.29 (s, 3H, 5′ NH-
CH3), 1.30 (t, 3H, 8CH2CH3).
5′ -Deoxy-5′ ,8-bis(methylamino)adenosine (9c). Compound 9c
was prepared by the same procedure as described for the preparation
of 9a using 8c (1.00 g, 3.17 mmol) and 33% methylamine/ethanol
solution (30 mL). After column chromatography (elution with 7:1:
0.4 chloroform:methanol:NH4OH), a yellow glassy solid was
obtained: 505 mg (51%). MS m/z 310 (M + H)+. 1H NMR (DMSO-
d6) δ 7.89 (bs and q, 2H, H-2 and 8CH3-NH), 6.44 (bs, 2H, 6-NH2),
5.84 (d, 1H, H-1′ , J1′ ,2′ ) 7.0 Hz), 5.22 (d, 1H, 2′ -OH, J2′ -2′ OH )
6.4 Hz), 5.12 (d, 1H, 3′ -OH, J3′ -3′ OH ) 4.0 Hz), 4.66 (ddd, 1H,
H-2′ , J1′ ,2′ ) 7.0 Hz, J2′ ,3′ ) 5.4 Hz, J2′ -2′ OH ) 6.4 Hz), 4.14 (bm,
1H, H-3′ ), 3.94-4.0 (bm, 1H, H-4′ ), 2.90 (d, 3H, 8NH-CH3, J )
4.4 Hz), 2.77-2.83 (m, 1H, 5′ -CH2), 2.57-2.62 (m, 1H, 5′ -CH2),
2.35 (s, 3H, 5′ NH-CH3).
5′ -Deoxy-5′ -methylamino-8-phenyladenosine (9d). Compound 9d
was prepared by the same procedure as described for the preparation
of 9a using 8d (2.00 g, 5.52 mmol) and 33% methylamine/ethanol
solution (40 mL). After column chromatography (elution with 4:1:
0.2 chloroform:methanol:NH4OH), a yellow glassy solid was
obtained: 963 mg (49%). MS m/z 357 (M + H)+. 1H NMR (DMSO-
d6) δ 8.19 (s, 1H, H-2), 7.72-7.76 (m, 2H, 8-phenyl o-H’s),
7.58-7.61 (m, 3H, 8-phenyl m- and p-H’s), 7.40 (bs, 2H, 6-NH2),
5.70 (d, 1H, H-1′ , J1′ ,2′ ) 6.4 Hz), 5.38 (d, 1H, 2′ -OH, J2′ -2′ OH )
6.2 Hz), 5.29 (ddd, 1H, H-2′ , J1′ ,2′ ) 6.4 Hz, J2′ ,3′ ) 5.1 Hz, J2′ -2′ OH
) 6.2 Hz), 5.14 (bs, 1H, 3′ -OH), 4.19 (bs, 1H, H-3′ ), 3.95-4.0
(m, 1H, H-4′ ), 2.82 (d, 2H, 5′ -CH2, J ) 5.2 Hz), 2.34 (s, 3H, 5′ NH-
CH3).
5′ -Deoxy-5′ -[[2-[[(1-ethoxyethylidene)amino]oxy]ethyl]methyl-
amino]-8-methyladenosine (11a). A mixture of compound 9a (416
mg, 1.41 mmol), ethyl N-(2-bromoethoxy)ethanimidate
28 (350 mg,
1.66 mmol), and diisopropylethylamine (DIEA) (11 mg, 0.014 mL,
0.085 mmol) in DMF (5 mL) was heated at 50 °C overnight under
nitrogen. The reaction mixture was concentrated to dryness. The
resulting syrup was puriﬁed by column chromatography (elution
with 7:1:0.1 chloroform:methanol:NH4OH) to yield 50 mg (8%)
of a yellow glassy sticky solid. MS m/z 424 (M + H)+. 1H NMR
(DMSO-d6) δ 8.07 (s, 1H, H-2), 7.11 (bs, 2H, 6-NH2), 5.73 (d,
1H, H-1′ , J1′ ,2′ ) 5.5 Hz), 4.31 (d, 1H, 2′ -OH, J2′ -2′ OH ) 6.3 Hz),
5.15 (d, 1H, 3′ -OH, J3′ -3′ OH ) 5.5 Hz), 5.04 (ddd, 1H, H-2′ , J1′ ,2′
) 5.5 Hz, J2′ ,3′ ) 5.1 Hz, J2′ -2′ OH ) 6.3 Hz), 4.13 (ddd, 1H, H-3′ ,
J2′ ,3′ ) 5.1 Hz, J3′ ,4′ ) 4.7 Hz, J3′ -3′ OH ) 5.5 Hz), 3.92 (q, 2H,
CH2CH3), 3.88 (t, 2H, NO-CH2), 2.72-2.78 (m, 1H, 5′ -CH2),
2.56-2.62 (m, 4H, 5′ -CH2, H-4′ , N(CH3)-CH2), 2.53 (s, 3H, 8-CH3),
2.21 (s, 3H, N-CH3), 1.83 (s, 3H, C-CH3), 1.19 (t, 3H, OCH2CH3).
5′ -Deoxy-5′ -[[2-[[(1-ethoxyethylidene)amino]oxy]ethyl]methyl-
amino]-8-(methylamino)adenosine (11b). Compound 11b was
prepared by the same procedure as reported for 11a using 9c (500
mg, 1.61 mmol), ethyl N-(2-bromoethoxy)ethanimidate
28 (407 mg,
1.93 mmol), DIEA (104 mg, 0.14 mL, 0.80 mmol), and DMF (5
mL). After column chromatography (elution with 7:1:0.3 chloroform:
methanol:NH4OH), a yellow glassy sticky solid was obtained: yield
209 mg (30%). MS: m/z 439 (M + H)+. 1H NMR (DMSO-d6) δ
7.89 (s, 1H, H-2), 6.85 (q, 1H, 8CH3-NH), 6.47 (bs, 2H, 6-NH2),
5.69 (d, 1H, H-1′ , J1′ ,2′ ) 5.0 Hz), 5.27 (d, 1H, 2′ -OH, J2′ -2′ OH )
5.5 Hz), 5.06 (d, 1H, 3′ -OH, J3′ -3′ OH ) 5.0 Hz), 4.88 (ddd, 1H,
H-2′ , J1′ ,2′ ) 5.0 Hz, J2′ ,3′ ) 5.8 Hz, J2′ -2′ OH ) 5.5 Hz), 4.17 (ddd,
1H, H-3′ , J2′ ,3′ ) 5.8 Hz, J3′ ,4′ ) 4.7 Hz, J3′ -3′ OH ) 5.0 Hz),
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(d, 3H, 8NH-CH3, J ) 4.6 Hz), 2.71-2.77 (m, 1H, 5′ -CH2),
2.56-2.67 (m, 3H, 5′ -CH2, N(CH3)-CH2), 2.24 (s, 3H, N-CH3),
1.83 (s, 3H, C-CH3), 1.19 (t, 3H, OCH2CH3).
5′ -Deoxy-5′ -[[2-[[(1-ethoxyethylidene)amino]oxy]ethyl]methyl-
amino]-8-phenyladenosine (11c). The procedure described for 11a
was used to prepare 11c from 9d (400 mg, 1.12 mmol), ethyl N-(2-
bromoethoxy)ethanimidate
28 (283 mg, 1.34 mmol), and DIEA (72
mg, 0.10 mL, 0.55 mmol). After column chromatography (elution
with 7:1 chloroform:methanol), a yellow glassy sticky solid was
obtained: yield 105 mg (20%). MS: m/z 486 (M + H)+. 1H NMR
(DMSO-d6) δ 8.17 (s, 1H, H-2), 7.72-7.78 (m, 2H, 8-phenyl
o-H’s), 7.58-7.63 (m, 3H, 8-phenyl m- and p-H’s), 7.36 (bs, 2H,
6-NH2), 5.67 (d, 1H, H-1′ , J1′ ,2′ ) 5.2 Hz), 5.29-5.34 (m, 2H, 2′ -
OH, H-2′ ), 5.13 (d, 1H, 3′ -OH, J3′ -3′ OH ) 5.3 Hz), 4.14-4.18 (m,
1H, H-3′ ), 3.88-3.97 (m, 3H, H-4′ , NO-CH2), 3.92 (q, 2H,
CH2CH3), 2.78-2.84 (m, 1H, 5′ -CH2), 2.60-2.70 (m, 3H, 5′ -CH2,
N(CH3)-CH2), 2.24 (bs, 3H, N-CH3), 1.83 (s, 3H, C-CH3), 1.19 (t,
3H, OCH2CH3).
5′ -[(2-Aminooxyethyl)methylamino]-5′ -deoxy-8-methyladenos-
ine sulfate (2.2:1 salt) (12a). Compound 11a (50 mg, 0.11 mmol)
was dissolved in 2 mL of2NH 2SO4 and stirred for two days at
room temperature. The reaction mixture was neutralized with
NaHCO3 and lyophilized. The compound was extracted with EtOH
(2 × 10 mL) and concentrated to dryness. The residue was puriﬁed
by column chromatography (silica gel 230-400 mesh, elution with
7:1:0.3 chloroform:methanol:NH4OH). The desired fractions were
combined, concentrated, and dried in vacuo. The product was
dissolved in 3 mL of EtOH and2NH 2SO4 was added dropwise.
The resulting sulfate salt that precipitated out was ﬁltered and then
washed with EtOH. This product, which was hygroscopic in nature,
was dissolved in water (2 mL) and lyophilized to give a white solid:
yield 20 mg (29%). MS: m/z 354 (M + H)+. 1H NMR (DMSO-d6)
δ 8.25 (s, 1H, H-2), 7.80 (bs, 2H, O-NH2), 5.87 (d, 1H, H-1′ , J1′ ,2′
) 5.7 Hz), 4.88 (t, 1H, H-2′ , J2′ ,3′ ) 5.2 Hz), 4.35-4.40 (bm, 1H,
H-4′ ), 4.23 (t, 1H, H-3′ , J2′ ,3′ ) 3.2 Hz), 4.10 (t, 2H, NH2O-CH2),
3.50-3.57 (m, 1H, 5′ -CH2), 3.65-3.72 (m, 1H, 5′ -CH2), 3.45 (bm,
2H, N(CH3)-CH2), 2.85 (s, 3H, N-CH3), 2.58 (s, 3H, 8-CH3). UV
λmax, nm, pH 1, 274 (ε 15200), pH 7, 276 (ε 15500), pH 13, 277
(ε 15900). Anal. (C14H23N7O4·2.2H2SO4·0.1C2H5OH·0.5H2O) C,
H, N.
5′ -[(2-Aminooxyethyl)methylamino]-5′ -deoxy-8-(methylamino)ad-
enosine sulfate (2.1:1 salt) (12b). The procedure described for 12a
was used to prepare 12b from 11b (200 mg, 0.45 mmol): yield
125 mg (46%). MS: m/z 369 (M + H)+. 1H NMR (DMSO-d6) δ
8.16 (s, 1H, H-2), 7.50-7.65 (bm, 2H, O-NH2), 5.83 (d, 1H, H-1′ ,
J1′ ,2′ ) 5.3 Hz), 6.56 (bs, 2H, 6-NH2), 4.96 (t, 1H, H-2′ , J2′ ,3′ ) 4.8
Hz), 4.28-4.35 (bm, 1H, H-4′ ), 4.25 (t, 1H, H-3′ , J3′ ,4′ ) 4.1 Hz),
3.96 (t, 2H, NH2O-CH2), 3.59-3.66 (m, 1H, 5′ -CH2), 3.49-3.57
(m, 1H, 5′ -CH2), 3.36-3.40 (bm, 2H, N(CH3)-CH2), 2.94 (s, 3H,
8NH-CH3), 2.81 (s, 3H, N-CH3). UV λmax, nm, pH 1, 274 (ε 14300),
pH 7, 276.7 (ε 17100), pH 13, 276.1 (ε 17500). Anal.
(C14H24N8O4·2.1H2SO4·0.3C2H5OH·0.2H2O) C, H, N, S.
5′ -[(2-Aminooxyethyl)methylamino]-5′ -deoxy-8-phenyladenos-
ine sulfate (2:1 salt) (12c). Compound 12c was prepared by the
same procedure as described for the preparation of 12a using 11c
(99 mg, 0.20 mmol): yield 57 mg (42%). MS: m/z 416 (M + H)+.
1H NMR (D2O) δ 8.37 (s, 1H, H-2), 7.73-7.76 (m, 2H, 8-phenyl
o-H’s), 7.60-7.70 (m, 3H, 8-phenyl m- and p-H’s), 6.02 (d, 1H,
H-1′ , J1′ ,2′ ) 5.7 Hz), 5.25 (t, 1H, H-2′ , J2′ ,3′ ) 4.9 Hz), 4.46-4.54
(bm, 2H, H-3′ ,4 ′ ), 4.03 (t, 2H, NH2O-CH2), 3.87-4.0 (m, 1H,
5′ -CH2), 3.61-3.67 (m, 1H, 5′ -CH2), 3.50-3.55 (m, 2H, N(CH3)-
CH2), 3.0 (s, 3H, N-CH3). UV λmax, nm, pH 1, 275 (ε 21600), pH
7, 275 (ε 17100), pH 13, 274.4 (ε 16800). Anal. (C19H25N7O4
·2.0H2SO4·3H2O) C, H, N, S.
5′ -Deoxy-5′ -[[4-[[(1-ethoxyethylidene)amino]oxy]butyl]methyl-
amino]-8-(methylamino)adenosine (13a). Compound 13a was pre-
pared by the same procedure as reported for 11a using 9c (1.00 g,
3.23 mmol), ethyl N-(4-bromobutoxy)ethanimidate
29 (924 mg, 3.87
mmol), and DIEA (209 mg, 0.28 mL, 1.6 mmol): yield 635 mg
(42%). MS: m/z 467 (M + H)+. 1H NMR (DMSO-d6) δ 7.89 (s,
1H, H-2), 6.87 (q, 1H, 8CH3-NH), 6.46 (bs, 2H, 6-NH2), 5.69 (d,
1H, H-1′ , J1′ ,2′ ) 4.8 Hz), 5.25 (d, 1H, 2′ -OH, J2′ -2′ OH ) 5.6 Hz),
5.06 (d, 1H, 3′ -OH, J3′ -3′ OH ) 5.4 Hz), 4.91 (ddd, 1H, H-2′ , J1′ ,2′
) 4.8 Hz, J2′ ,3′ ) 5.4 Hz, J2′ -2′ OH ) 5.6 Hz), 4.16 (ddd, 1H, H-3′ ,
J2′ ,3′ ) 5.4 Hz, J3′ ,4′ ) 4.9 Hz, J3′ -3′ OH ) 5.4 Hz), 3.85-3.94 (m,
1H, H-4′ ), 3.92 (q, 2H, OCH2CH3), 3.80 (t, 2H, NO-CH2), 2.88 (d,
3H, 8NH-CH3, J ) 4.6 Hz), 2.65-2.74 (m, 1H, 5′ -CH2), 2.46-2.58
(m, 1H, 5′ -CH2), 2.34 (t, 2H, N(CH3)-CH2), 2.17 (s, 3H, N-CH3),
1.83 (s, 3H, C-CH3), 1.37-1.61 (bm, 4H, NOCH2-CH2CH2), 1.19
(t, 3H, OCH2CH3).
5′ -Deoxy-5′ -[[4-[[(1-ethoxyethylidene)amino]oxy]butyl]methyl-
amino]-8-phenyladenosine (13b). The same procedure as described
for 6a was used to prepare 13b from 9d (450 mg, 1.26 mmol),
ethyl N-(4-bromobutoxy)ethanimidate
29 (360 mg, 1.51 mmol), and
DIEA (81 mg, 0.10 mL, 0.62 mmol). After column chromatography
(elution with 7:1 chloroform:methanol), a yellow glassy sticky solid
was obtained: yield 312 mg (48%). MS: m/z 514 (M + H)+. 1H
NMR (DMSO-d6) δ 8.17 (s, 1H, H-2), 7.71-7.78 (m, 2H, 8-phenyl
o-H’s), 7.58-7.64 (m, 3H, 8-phenyl m- and p-H’s), 7.36 (bs, 2H,
6-NH2), 5.67 (d, 1H, H-1′ , J1′ ,2′ ) 5.7 Hz), 5.32 (bs, 1H, 2′ -OH),
5.31 (t, 1H, H-2′ , J1′ ,2′ ) 5.7 Hz, J2′ ,3′ ) 5.4 Hz), 5.11 (d, 1H, 3′ -
OH, J3′ -3′ OH ) 4.8 Hz), 4.16 (bddd, 1H, H-3′ , J2′ ,3′ ) 5.4 Hz, J3′ ,4′
) 4.0 Hz), 3.92-3.97 (m, 1H, H-4′ ), 3.91 (q, 2H, OCH2CH3), 3.79
(t, 2H, NO-CH2), 2.72-2.80 (m, 1H, 5′ -CH2), 2.54-2.59 (m, 1H,
5′ -CH2), 2.34 (bt, 2H, N(CH3)-CH2), 2.17 (bs, 3H, N-CH3), 1.83
(s, 3H, C-CH3), 1.39-1.60 (bm, 4H, NOCH2-CH2CH2), 1.18 (t,
3H, OCH2CH3).
5′ -Deoxy-5′ -[[4-[[(1-ethoxyethylidene)amino]oxy]butyl]methyl-
amino]-8-oxoadenosine (13c). The procedure described for 11a was
used to prepare 13c from 9i
52 (500 mg, 1.68 mmol), ethyl N-(4-
bromobutoxy)ethanimidate
29 (481 mg, 2.01 mmol), DIEA (109 mg,
0.14 mL, 0.84 mmol), and DMF (5 mL). After column chroma-
tography (elution with 4:1:0.2 chloroform:methanol:NH4OH), a
yellow glassy sticky solid was obtained: yield 200 mg (26%). MS:
m/z 454 (M + H)+. 1H NMR (DMSO-d6) δ 10.34 (bs, 1H, 8-OH),
8.02 (s, 1H, H-2), 6.49 (bs, 2H, 6-NH2), 5.62 (d, 1H, H-1′ , J1′ ,2′ )
5.0 Hz), 4.99 (bs, 1H, 3′ -OH), 5.19 (bs, 1H, 2′ -OH), 4.90 (t, 1H,
H-2′ , J2′ ,3′ ) 5.4 Hz), 4.16-4.24 (bm, 1H, H-3′ ), 3.83-3.89 (m,
1H, H-4′ ), 3.92 (q, 2H, OCH2CH3), 3.77 (t, 2H, NO-CH2),
2.62-3.68 (m, 1H, 5′ -CH2), 2.40-2.46 (m, 1H, 5′ -CH2), 2.30 (t,
2H, N(CH3)-CH2), 2.13 (s, 3H, N-CH3), 1.84 (s, 3H, C-CH3),
1.35-1.60 (bm, 4H, NOCH2-CH2CH2), 1.21 (t, 3H, OCH2CH3).
5′ -Deoxy-2′ ,3′ -isopropylidene-5′ -[[4-[[(1-ethoxyethylidene)ami-
no]oxy]butyl]methylamino]-8-methyladenosine (13d). Compound
13d was prepared by the same procedure as reported for 11a using
9e (1.00 g, 3.11 mmol), MsCl (392 mg, 0.26 mL, 3.42 mmol),
methylamine (25 mL), ethyl N-(4-bromobutoxy)ethanimidate (853
mg, 3.58 mmol), DIEA (200 mg, 0.27 mL, 1.54 mmol), and DMF
(8 mL). After column chromatography (95:5 chloroform:methanol),
a glassy solid was obtained: yield 176 mg (12%). MS: m/z 492 (M
+ H)+. 1H NMR (CDCl3) δ 8.27 (s, 1H, H-2), 5.99 (d, 1H, H-1′ ,
J1′ ,2′ ) 1.8 Hz), 5.75 (dd, 1H, H-2′ , J1′ ,2′ ) 1.8 Hz, J2′ ,3′ ) 6.4 Hz),
5.39 (bs, 2H, 6-NH2), 5.08 (dd, 1H, H-3′ , J2′ ,3′ ) 6.4 Hz, J3′ ,4′ )
3.5 Hz), 4.27-4.34 (m, 1H, H-4′ ), 4.0 (q, 2H, OCH2CH3), 3.84 (t,
2H, NO-CH2), 2.64 (s, 3H, 8-CH3), 2.55-2.61 (m, 1H, 5′ -CH2),
2.45-2.55 (m, 1H, 5′ -CH2), 2.29-2.34 (m, 2H, N(CH3)-CH2), 2.21
(s, 3H, N-CH3), 1.91 (s, 3H, C-CH3), 1.61 and 1.40 (2s, 6H,
C(CH3)2), 1.51-1.60 (m, 2H, NOCH2-CH2), 1.37-1.45 (m, 2H,
N(CH3)CH2-CH2), 1.27 (t, 3H, OCH2CH3).
5′ -Deoxy-2′ ,3′ -isopropylidene-5′ -[[4-[[(1-ethoxyethylidene)ami-
no]oxy]butyl]methylamino]-8-ethyladenosine (13e). The procedure
described for 11a was used to prepare 13e from 9f (1.00 g, 2.98
mmol), MsCl (375 mg, 0.25 mL, 3.27 mmol), methylamine (25
mL), ethyl N-(4-bromobutoxy)ethanimidate (852 mg, 3.57 mmol),
DIEA (192 mg, 0.25 mL, 1.48 mmol), and DMF (10 mL). After
column chromatography (95:5 chloroform:methanol), a glassy solid
was obtained: yield 159 mg (11%). MS: m/z 506 (M + H)+. 1H
NMR (CDCl3) δ 8.27 (s, 1H, H-2), 5.99 (d, 1H, H-1′ , J1′ ,2′ ) 2.0
Hz), 5.73 (dd, 1H, H-2′ , J1′ ,2′ ) 2.0 Hz, J2′ ,3′ ) 6.4 Hz), 5.40 (bs,
2H, 6-NH2), 5. 09 (dd, 1H, H-3′ , J2′ ,3′ ) 6.4 Hz, J3′ ,4′ ) 3.6 Hz),
4.26-4.33 (m, 1H, H-4′ ), 4.0 (q, 2H, O CH2CH3), 3.84 (t, 2H,
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5′ -CH2), 2.46-2.53 (m, 1H, 5′ -CH2), 2.30-2.35 (m, 2H, N(CH3)-
CH2), 2.21 (s, 3H, N-CH3), 1.91 (s, 3H, C-CH3), 1.61 and 1.40
(2s, 6H, C(CH3)2), 1.51-1.59 (m, 2H, NOCH2-CH2), 1.49-1.38
(m, 2H, N(CH3)CH2-CH2), 1.43 (s, 3H, CH3 of 8-Et), 1.27 (t, 3H,
OCH2CH3).
5′ -Deoxy-2′ ,3′ -isopropylidene-5′ -[[4-[[(1-ethoxyethylidene)ami-
no]oxy]butyl]methylamino]-adenosine (13f). Compound 13f was
prepared by the same procedure as reported for 11a using 9g
32
(1.00 g, 3.25 mmol), MsCl (447 mg, 0.30 mL, 3.90 mmol),
methylamine (25 mL), ethyl N-(4-bromobutoxy)ethanimidate (511
mg, 2.15 mmol), DIEA (125 mg, 0.17 mL, 0.96 mmol), and DMF
(5 mL). After column chromatography (95:5 chloroform:methanol),
a pale-yellow syrup was obtained: yield 839 mg (86%). MS: m/z
478 (M + H)+. 1H NMR (CDCl3) δ 8.36 (s, 1H, H-2), 7.96 (s, 1H,
H-8), 6.07 (d, 1H, H-1′ , J1′ ,2′ ) 2.2 Hz), 5.60 (bs, 2H, 6-NH2),
5.49 (dd, 1H, H-2′ , J1′ ,2′ ) 2.2 Hz, J2′ ,3′ ) 6.4 Hz), 4.95 (dd, 1H,
H-3′ , J2′ ,3′ ) 6.4 Hz, J3′ ,4′ ) 3.4 Hz), 4.36-4.40 (m, 1H, H-4′ ), 4.0
(q, 2H, OCH2CH3), 3.86 (t, 2H, NO-CH2), 2.61 (dd, 1H, 5′ -CH2),
2.55 (dd, 1H, 5′ -CH2), 2.38 (bt, 2H, N(CH3)-CH2), 2.26 (s, 3H,
N-CH3), 1.91 (s, 3H, C-CH3), 1.61 and 1.40 (2s, 6H, C(CH3)2),
1.55-1.61 (m, 2H, NOCH2-CH2), 1.44-1.52 (m, 2H, N(CH3)CH2-
CH2), 1.27 (t, 3H, OCH2CH3).
5′ -[(4-Aminooxybutyl)methylamino]-5′ -deoxy-8-(methylamino)ad-
enosine sulfate (0.4:1 salt) (14a). The same procedure used to
prepare 12a was used to prepare 14a using 13a (600 mg, 1.28
mmol) and2NH 2SO4 (10 mL): yield 514 mg (87%). MS: m/z
510 (M + H)+. 1H NMR (DMSO-d6) δ 7.91 (s, 1H, H-2), 6.88
(bq, 1H, 8CH3-NH), 6.50 (bs, 2H, 6-NH2), 5.72 (d, 1H, H-1′ , J1′ ,2′
) 5.1 Hz), 5.08-5.39 (bm, 2H, 2′ ,3 ′ -OH), 4.0-5.02 (m, 1H, H-2′ ),
4.19 (t, 1H, H-3′ ), 3.94-4.06 (bm, 1H, H-4′ ), 3.45 (bt, 2H, NH2O-
CH2), 3.36-3.54 (m, 2H, 5′ -CH2), 2.89 (d, 3H, 8NH-CH3),
2.78-2.95 (bm, 2H, NCH3-CH2), 2.04 (bs, 3H, N-CH3), 1.38-1.52
(bm, 4H, NH2OCH2-CH2CH2). UV λmax, nm, pH 1, 274.8 (ε
14300), pH 7, 276 (ε 16700), pH 13, 277 (ε 17400). Anal.
(C16H28N8O4·0.4H2SO4·0.2C2H5OH·0.9H2O) C, H, N, S.
5′ -[(4-Aminooxybutyl)methylamino]-5′ -deoxy-8-phenyladenos-
ine sulfate (1.75:1 salt) (14b). Compound 14b was prepared by the
same procedure as described for the preparation of 12a using 13b
(305 mg, 0.59 mmol) and2NH 2SO4 (4 mL): yield 252 mg (64%).
MS: m/z 444 (M + H)+. 1H NMR (DMSO-d6) δ 8.18 (s, 1H, H-2),
7.20-7.78 (m, 2H, 8-phenyl o-H’s), 7.59-7.61 (m, 3H, 8-phenyl
m- and p-H’s), 7.37 (bs, 2H, 6-NH2), 5.85 (s, 2H, O-NH2), 5.68 (d,
1H, H-1′ , J1′ ,2′ ) 5.7 Hz), 5.31 (t, 1H, H-2′ , J2′ ,3′ ) 5.5 Hz), 5.13
(bd, 1H, 3′ -OH), 4.18 (t, 1H, H-3′ , J3′ ,4′ ) 3.9 Hz), 3.94-3.99 (bm,
1H, H-4′ ), 3.49 (t, 2H, NH2O-CH2), 2.73-2.79 (m, 1H, 5′ -CH2),
2.54-2.62 (m, 1H, 5′ -CH2), 2.27-2.36 (bm, 2H, N(CH3)-CH2),
2.16 (bs, 3H, N-CH3), 1.33-1.53 (bm, 4H, NH2OCH2-CH2CH2).
1H NMR (D2O) δ 8.36 (s, 1H, H-2), 7.72-7.78 (m, 2H, 8-phenyl
o-H’s), 7.63-7.71 (m, 3H, 8-phenyl m- and p-H’s), 6.02 (d, 1H,
H-1′ , J1′ ,2′ ) 5.8 Hz), 5.28-5.41 (bm, 1H, H-2′ ), 4.43-4.53 (bm,
2H, H-3′ ,4 ′ ), 3.92-4.03 (m, 1H, 5′ -CH2), 3.90 (t, 2H, NH2O-CH2),
3.49-3.59 (m, 1H, 5′ -CH2), 3.22- 3.32 (bm, 2H, N(CH3)-CH2),
2.92 (bs, 3H, N-CH3), 1.61-1.83 (bm, 4H, NH2OCH2-CH2CH2).
UV λmax, nm, pH 1, 275 (ε 21400), pH 7, 274.5 (ε 16900), pH 13,
274.8 (ε 16,700). Anal. (C21H29N7O4·1.75H2SO4·0.05C2H5OH·
2.4H2O) C, H, N, S.
5′ -[(4-Aminooxybutyl)methylamino]-5′ -deoxy-8-oxoadenosine sul-
fate (1.9:1 salt) (14c). The procedure was the same as reported above
for 12a using 13c (190 mg, 0.41 mmol) and2NH 2SO4 (3 mL).
The compound was puriﬁed by column chromatography (elution
with 4:1:0.5 chloroform:methanol:NH4OH): yield 208 mg (82%).
MS: m/z 384 (M + H)+. 1H NMR (DMSO-d6) δ 10.45 (bs, 1H,
8-OH), 8.05 (s, 1H, H-2), 6.58 (bs, 2H, 6-NH2), 5.77 (d, 1H, H-1′ ,
J1′ ,2′ ) 5.0 Hz), 5.37-5.71 (bm, 2H, O-NH2), 4.83 (t, 1H, H-2′ ,
J2′ ,3′ ) 4.2 Hz), 4.18-4.29 (m, 2H, H-3′ , H-4′ ), 3.88 (t, 2H, NH2O-
CH2), 3.34-3.54 (m, 2H, 5′ -CH2), 3.06 (bt, 2H, N(CH3)-CH2), 2.73
(s, 3H, N-CH3), 1.46-1.74 (bm, 4H, NH2OCH2-CH2CH2). UV
λmax, nm, pH 1, 263.3 (ε 12200), pH 7, 268.9 (ε 13600), pH 13,
279.9 (ε 15,600). Anal. (C15H25N7O5·1.9H2SO4·0.1C2H5OH·2H2O)
C, H, N, S.
5′ -[(4-Aminooxybutyl)methylamino]-5′ -deoxy-8-methyladenos-
ine sulfate (1.9:1 salt) (14d). Compound 13d (149 mg, 0.30 mmol)
was dissolved in 2.5 mL of1NH 2SO4 and stirred for 12 days at
room temperature. After a work up identical with that used for 7a,
the residue was puriﬁed by column chromatography (silica gel
230-400 mesh, elution with 4:1:0.2 chloroform:methanol:NH4OH).
The product was dissolved in 8 mL of EtOH and2NH 2SO4 was
added dropwise. The sulfate salt that precipitated out was ﬁltered
and washed with EtOH. This product was dissolved in water (2
mL) and lyophilized to give a white solid: yield 59 mg (33%). MS:
m/z 382 (M + H)+. 1H NMR (D2O) δ 8.39 (s, 1H, H-2), 6.08 (d,
1H, H-1′ , J1′ ,2′ ) 5.5 Hz), 5.0-5.19 (bm, 1H, H-2′ ), 4.51-4.58
(bm, 2H, H-3′ ,4 ′ ), 4.08 (t, 2H, NH2O-CH2), 3.73-4.0 (m, 1H,
5′ -CH2), 3.44-3.69 (m, 1H, 5′ -CH2), 3.16-3.36 (bm, 2H, N(CH3)-
CH2), 2.92 (bs, 3H, N-CH3), 2.70 (s, 3H, 8-CH3), 1.68-1.88 (bm,
4H, NH2OCH2-CH2CH2). UV λmax, nm, pH 1, 258.2 (ε 15400),
pH 7, 259.7 (ε 15500), pH 13, 260.9 (ε 15900). Anal.
(C16H27N7O4·1.9H2SO4·0.4C2H5OH) C, H, N.
5′ -[(4-Aminooxybutyl)methylamino]-5′ -deoxy-8-ethyladenos-
ine sulfate (1.9:1 salt) (14e). The procedure was the same as reported
above for 14d using 13e (155 mg, 0.30 mmol): yield 55 mg (30%).
MS: m/z 396 (M + H)+. 1H NMR (D2O) δ8.39 (s, 1H, H-2), 6.09
(d, 1H, H-1′ , J1′ ,2′ ) 5.6 Hz), 5.07-5.23 (bm, 1H, H-2′ ), 4.50-4.60
(bm, 2H, H-3′ ,4 ′ ), 4.06 (t, 2H, NH2O-CH2), 3.82-3.96 (m, 1H,
5′ -CH2), 3.45-3.69 (m, 1H, 5′ -CH2), 3.27 (bs, 2H, N(CH3)-CH2),
3.0-3.10 (m, 2H, 8CH2CH3), 2.91 (bs, 3H, N-CH3), 1.68-1.86
(bm, 4H, NH2OCH2-CH2CH2), 1.39 (t, 3H, 8CH2CH3). UV λmax,
nm, pH 1, 259.1 (ε 16400), pH 7, 260 (ε 15700), pH 13, 260.2 (ε
15900). Anal. (C17H29N7O4·1.9H2SO4·0.2C2H5OH) C, H, N.
5′ -[(4-Aminooxybutyl)methylamino]-5′ -deoxyadenosine sulfate
(2:1 salt) (14f). The procedure was the same as reported above for
14d using 13f (750 mg, 1.5 mmol): yield 457 mg (48%). MS: m/z
368 (M + H)+. 1H NMR (DMSO-d6) δ 8.43 (s, 1H, H-8), 8.23 (s,
1H, H-2), 7.58 (bs, 2H, 6-NH2), 6.03 (d, 1H, H-1′ , J1′ ,2′ ) 5.4 Hz),
4.75 (t, 1H, H-2′ , J1′ ,2′ ) 5.4 Hz, J2′ ,3′ ) 4.8 Hz), 4.32-4.40 (bm,
1H, H-4′ ), 4.23 (t, 1H, H-3′ , J3′ ,4′ ) 3.8 Hz), 3.93 (t, 2H, NH2O-
CH2), 3.68 (dd, 1H, 5′ -CH2), 3.49 (bdd, 1H, 5′ -CH2), 3.13 (bt, 2H,
N(CH3)-CH2), 2.80 (s, 3H, N-CH3), 1.50-1.78 (bm, 4H,
NH2OCH2-CH2CH2). Anal. (C15H25N7O4·2.0H2SO4·0.3C2H5OH·
1.5H2O) C, H, N, S.
5′ -Deoxy-2′ ,3′ -O-isopropylidene-5′ -[(2-hydroxyethyl)methylami-
no]adenosine (15). Compound 8i
52 (8.20 g, 17.79 mmol) was
dissolved in 2-(methylamino)ethanol (54 mL, 673 mmol) and stirred
at room temperature for 41 h. The solvent was evaporated to give
a yellow residue. The residue was dissolved in 100 mL of
chloroform and washed with NaHCO3 (3 × 50 mL). The organic
layer was dried over Na2SO4 and concentrated to dryness to give
yellow foam. The residue was puriﬁed by column chromatography
(silica gel 230-400 mesh, elution with 9:1:0.1 chloroform:
methanol:NH4OH) to yield 2.55 g (39%). MS: m/z 365 (M + H)+.
1H NMR (DMSO-d6) δ 8.34 (s, 1H, H-2), 8.18 (s, 1H, H-8), 7.33
(bs, 2H, 6-NH2), 6.13 (d, 1H, H-1′ , J1′ ,2′ ) 2.5 Hz), 5.48 (dd, 1H,
H-2′ , J2′ ,3′ ) 6.3 Hz), 4.96 (dd, 1H, H-3′ , J3′ ,4′ ) 3.0 Hz), 4.33 (t,
1H, OH), 4.24 (dt, 1H, H-4′ ), 3.44 (t, 2H, OH-CH2), 2.64 (dd, 1H,
5′ -CH2), 2.35-2.49 (m, 3H, 5′ -CH2, N(CH3)-CH2), 2.18 (s, 3H,
N-CH3), 1.54 and 1.33 (2s, 6H, C(CH3)2).
5′ -Deoxy-2′ ,3′ -O-isopropylidene-5′ -[(2-phthalimidooxyethyl)meth-
ylamino]-adenosine (16). To a solution of compound 15 (989 mg,
2.714 mmol), N-hydroxyphthalimide (1.107 g, 6.786 mmol) and
P(Ph)3 (1.780 g, 6.787 mmol) in 50 mL of anhydrous THF was
added DEAD (1.07 mL, 6.8 mmol) in THF (10 mL) under nitrogen
over a period of 3 min at room temperature. After 5 min, 2% of
sodium carbonate (75 mL) was added to the reaction mixture
followed by dichloromethane (100 mL). The organic layer was
washed with 2% Na2CO3 (75 mL) and then with saturated NaCl (2
× 75 mL). The organic layer was dried over Na2SO4 and
concentrated to dryness to give a foam. The residue was puriﬁed
by column chromatography and eluted from the column with 1:3
dichloromethane:acetone to yield 842 mg (61%). MS: m/z 510 (M
+ H)+)+. 1H NMR (CDCl3) δ 8.36 (s, 1H, H-2), 8.07 (s, 1H, H-8),
7.79-7.83 (m, 2H, phthalimido aromatic H’s), 7.63-7.72 (m, 2H,
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(bs, 2H, 6-NH2), 5.49 (dd, 1H, H-2′ , J1′ ,2′ ) 2.2 Hz, J2′ ,3′ ) 6.4
Hz), 5.05 (dd, 1H, H-3′ , J2′ ,3′ ) 6.4 Hz, J3′ ,4′ ) 3.3 Hz), 4.40-4.45
(m, 1H, H-4′ ), 4.29 (t, 2H, NO-CH2), 2.89 (t, 2H, NOCH2-CH2),
2.83-2.89 (m, 1H, 5′ -CH2), 2.72-2.79 (m, 1H, 5′ -CH2), 2.40 (s,
3H, N-CH3), 1.62 and 1.40 (2s, 6H, C(CH3)2).
5′ -[(2-Aminooxyethyl)methylamino]-5′ -deoxyadenosine sulfate
(1:1 salt) (5). A solution of 16 (373 mg, 0.73 mmol) in1NH 2SO4
(5 mL) was heated at 60 °C for 3 h. The reaction mixture was
neutralized with NaHCO3 and lyophilized. The compound was
extracted with EtOH (2 × 20 mL) and concentrated to dryness.
The residue was puriﬁed by column chromatography, eluting with
77:20:3 chloroform:methanol:NH4OH). The product was dissolved
in 10 mL of EtOH and1NH 2SO4 was added dropwise with cooling
to precipitate the salt, which was ﬁltered and washed with EtOH
and dried in vacuo: yield 100 mg. MS: m/z 340 (M + H)+. 1H
NMR (DMSO-d6) δ 8.42 (s, 1H, H-8), 8.25 (s, 1H, H-2), 7.68 (bs,
2H, 6-NH2), 5.99 (d, 1H, H-1′ , J1′ ,2′ ) 5.3 Hz), 5.67 (t, 1H, H-2′ ,
J2′ ,3′ ) 4.6 Hz), 4.33-4.39 (bm, 1H, H-4′ ), 4.22 (t, 1H, H-3′ , J3′ ,4′
) 4.7 Hz), 4.06 (bt, 2H, NH2O-CH2), 3.63-3.71 (dd, 1H, 5′ -CH2),
3.52-3.59 (bdd, 1H, 5′ -CH2), 3.43 (bm, 2H, N(CH3)-CH2), 2.84
(s, 3H, N-CH3). UV λmax, nm, pH 1, 258.2 (ε 14,300), pH 7, 259
(ε 14,600), pH 13, 259 (ε 15,500). Anal. (C13H21N7O4·1.0
H2SO4·0.5C2H5OH·1.0H2O) C, H, N.
5′ -[(2-Carboethoxyethyl)methylamino]-5′ -deoxy-8-methyl-
adenosine (17a). A mixture of 9a (500 mg, 1.69 mmol), ethyl
3-chloropropionate (270 mg, 1.97 mmol), DIEA (109 mg, 0.14 mL,
0.84 mmol), and DMF (5 mL) was heated at 60 °C for two days.
Starting material remained but because the solution was getting
darker, heating was stopped. The reaction mixture was concentrated
to dryness. The product was puriﬁed by column chromatography
(7:1:0.1 chloroform:methanol:NH4OH) to give a sticky solid: yield
210 mg (31%). MS m/z 395 (M + H)+. 1H NMR (DMSO-d6) δ
8.08 (s, 1H, H-2), 7.11 (bs, 2H, 6-NH2), 5.74 (d, 1H, H-1′ , J1′ 2′ )
5.6 Hz), 5.33 (bd, 1H, OH-2′ ), 5.16 (bd, 1H, OH-3′ ), 5.12 (bdd,
1H, H-2′ , J1′ ,2′ ) 5.6 Hz, J2′ ,3′ ) 5.5 Hz), 4.21 (bdd, 1H, H-3′ , J2′ ,3′
) 5.5 Hz, J3′ ,4′ ) 4.3 Hz), 4.01 (q, 2H, OCH2CH3), 3.91-4.00 (m,
1H, H-4′ ), 2.70-2.77 (m, 1H, 5′ -CH2), 2.54-2.66 (m, 3H, 5′ -CH2,
CO-CH2), 2.53 (s, 3H, 8-CH3), 2.38 (t, 2H, N(CH3)-CH2), 2.16 (bs,
3H, N-CH3), 1.15 (t, 3H, OCH2CH3).
5′ -[(2-Carboethoxyethyl)methylamino]-5′ -deoxy-8-ethyladenos-
ine (17b). Compound 17b was prepared by the same procedure as
described for the preparation of 17a using 9b (260 mg, 0.84 mmol),
ethyl 3-chloropropionate (138 mg, 1.0 mmol), DIEA (53 mg, 0.07
mL, 0.41 mmol), and DMF (4 mL). After column chromatography
(elution with 7:1:0.1 chloroform:methanol:NH4OH), a glassy sticky
solid was obtained: yield 153 mg (44%). MS: m/z 409 (M + H)+.
1H NMR (DMSO-d6) δ 8.08 (s, 1H, H-2), 7.10 (bs, 2H, 6-NH2),
5.71 (d, 1H, H-1′ , J1′ 2′ ) 5.5 Hz), 5.32 (bd, 1H, OH-2′ , J2′ -2′ OH )
5.0 Hz), 5.16 (bd, 1H, OH-3′ , J3′ -3′ OH ) 5.1 Hz), 5.12 (ddd, 1H,
H-2′ , J1′ ,2′ ) 5.5 Hz, J2′ ,3′ ) 5.7 Hz, J2′ -2′ OH ) 5.0 Hz), 4.14 (ddd,
1H, H-3′ , J2′ ,3′ ) 5.7 Hz, J3′ ,4′ ) 4.1 Hz, J3′ -3′ OH ) 5.1 Hz), 4.01
(q, 2H, OCH2CH3), 3.91-3.98 (m, 1H, H-4′ ), 2.87 (q, 2H, CH2 of
8-Et), 2.71-2.79 (m, 1H, 5′ -CH2), 2.51-2.65 (m, 3H, 5′ -CH2, CO-
CH2), 2.38 (t, 2H, N(CH3)-CH2), 2.16 (bs, 3H, N-CH3), 1.30 (t,
3H, CH3 of 8-Et), 1.15 (t, 3H, OCH2CH3).
5′ -[(Carboethoxymethyl)methyamino]-5′ -deoxy-8-methyladenos-
ine (17c). Compound 17c was prepared by the same procedure as
described for the preparation of 17a using 9a (415 mg, 1.41 mmol),
ethyl chloroacetate (207 mg, 0.18 mL, 1.68 mmol), DIEA (91 mg,
0.12 mL, 0.70 mmol), and DMF (5 mL): yield 204 mg (38%). MS:
m/z 381 (M + H)+. 1H NMR (DMSO-d6) δ 8.06 (s, 1H, H-2), 7.11
(bs, 2H, 6-NH2), 5.73 (d, 1H, H-1′ , J1′ 2′ ) 5.4 Hz), 5.33 (bd, 1H,
OH-2′ , J2′ -2′ OH ) 4.7 Hz), 5.19 (bd, 1H, OH-3′ , J3′ -3′ OH ) 4.9 Hz),
5.03 (ddd, 1H, H-2′ , J1′ ,2′ ) 5.4 Hz, J2′ ,3′ ) 5.7 Hz, J2′ -2′ OH ) 4.7
Hz), 4.17 (ddd, 1H, H-3′ , J2′ ,3′ ) 5.7 Hz, J3′ ,4′ ) 4.4 Hz, J3′ -3′ OH )
4.9 Hz), 4.02 (q, 2H, OCH2CH3), 3.92-3.99 (m, 1H, H-4′ ), 3.27
(bs, 2H, N(CH3)-CH2), 2.83-2.90 (m, 1H, 5′ -CH2), 2.70-2.79 (m,
1H, 5′ -CH2), 2.53 (s, 3H, 8-CH3), 2.31 (s, 3H, N-CH3), 1.13 (t,
3H, OCH2CH3). UV λmax, nm, pH 1, 258.9 (ε 16100), pH 7, 260 (ε
15900), pH 13, 260.1 (ε 16200). Anal. (C16H24N6O5·0.5CHCl3·
0.3CH3OH) C, H, N.
5′ -[(2-Carboxamidoethyl)methylamino]-5′ -deoxy-8-methylade-
nosine sulfate (1.5:1 salt) (17d). Compound 17a (89 mg, 0.22 mmol)
was dissolved in 5 mL of methanolic ammonia and stirred for ﬁve
days at room temperature. The reaction mixture was concentrated
to dryness and puriﬁed by column chromatography (4:1:0.2
chloroform:methanol:NH4OH). The product was dissolved in 8 mL
of EtOH and2NH 2SO4 was added dropwise. The salt that
precipitated out was ﬁltered and washed with EtOH. This product,
which was hygroscopic in nature, was dissolved in water (2 mL)
and lyophilized to give a white solid: yield 65 mg (55%). MS: m/z
366 (M + H)+. 1H NMR (D2O) δ 8.43 (s, 1H, H-2), 6.09 (d, 1H,
H-1′ , J1′ ,2′ ) 5.9 Hz), 5.0-5.30 (bm, 1H, H-2′ ), 4.61-4.70 (bm,
1H, H-4′ ), 4.51-4.54 (bm, 1H, H-3′ ), 3.30-3.89 (bm, 5H, N-CH3
and N(CH3)-CH2), 2.96 (bs, 2H, 5′ -CH2), 2.77 (bs, 2H, NH2CO-
CH2), 2.70 (s, 3H, 8-CH3). UV λmax, nm, pH 1, 258.4 (ε 14900),
pH 7, 260.1 (ε 14900), pH 13, 260.1 (ε 15,300). Anal.
(C15H23N7O4·1.5H2SO4·0.8H2O) C, H, N, S.
5′ -[(2-Carboxamidoethyl)methyamino]-5′ -deoxy-8-ethyladenos-
ine sulfate (1.1:1 salt) (17e). The procedure was the same as reported
above for 17d using 17b (149 mg, 0.36 mmol) and methanolic
ammonia (5 mL): yield 94 mg (51%). MS: m/z 380 (M + H)+. 1H
NMR (DMSO-d6) δ 8.08 (s, 1H, H-2), 7.31 (bs, 1H, CO-NH2),
7.10 (bs, 2H, 6-NH2), 6.71 (bs, 1H, CO-NH2), 5.72 (d, 1H, H-1′ ,
J1′ 2′ ) 5.4 Hz), 5.31 (d, 1H, OH-2′ , J2′ -2′ OH ) 6.2 Hz), 5.16 (d,
1H, OH-3′ , J3′ -3′ OH ) 5.5 Hz), 5.09 (ddd, 1H, H-2′ , J1′ ,2′ ) 5.4 Hz,
J2′ ,3′ ) 5.7 Hz, J2′ -2′ OH ) 6.2 Hz), 4.17 (ddd, 1H, H-3′ , J2′ ,3′ ) 5.7
Hz, J3′ ,4′ ) 4.3 Hz, J3′ -3′ OH ) 5.5 Hz), 3.92-3.99 (m, 1H, H-4′ ),
2.87 (q, 2H, 8-CH2CH3), 2.69-2.75 (m, 1H, 5′ -CH2), 2.52-2.60
(m, 3H, CO-CH2, 5′ -CH2), 2.18 (bs, 2H, N(CH3)-CH2), 2.16 (s,
3H, N-CH3), 1.30 (t, 3H, CH3 of 8-Et). 1H NMR (D2O) δ 8.38 (s,
1H, H-2), 6.09 (d, 1H, H-1′ , J1′ ,2′ ) 6.2 Hz), 5.33 (bs, 1H, H-2′ ),
4.56-4.62 (m, 1H, H-4′ ), 4.51-4.54 (m, 1H, H-3′ ), 3.87-3.96 (bm,
2H, NH2CO-CH2), 3.56 (s, 3H, N-CH3), 2.98-3.80 (bm, 2H,
8-CH2CH3), 2.96 (bs, 2H, 5′ -CH2), 2.72-2.82 (m, 2H, N(CH3)-
CH2), 1.39 (s, 3H, CH3 of 8-Et). UV λmax, nm, pH 1, 259.4 (ε
15200), pH 7, 260.8 (ε 15100), pH 13, 260.6 (ε 15500). Anal.
(C16H25N7O4·1.1H2SO4·1.05H2O) C, H, N, S.
5′ -[(Carboxamidomethyl)methylamino]-5′ -deoxy-8-methylade-
nosine sulfate (1.45:1 salt) (17f). The same procedure used to prepare
17d was used to prepare 17f using 17c (200 mg, 0.52 mmol) and
methanolic ammonia (5 mL): yield 105 mg (39%). MS: m/z 352
(M + H)+. 1H NMR (DMSO-d6) δ 8.08 (s, 1H, H-2), 7.11 (bs,
2H, CO-NH2), 7.07 (bs, 2H, 6-NH2), 5.74 (d, 1H, H-1′ , J1′ 2′ ) 5.2
Hz), 5.34 (d, 1H, OH-2′ , J2′ -2′ OH ) 5.9 Hz), 5.21 (d, 1H, OH-3′ ,
J3′ -3′ OH ) 5.7 Hz), 4.97 (ddd, 1H, H-2′ , J1′ ,2′ ) 5.2 Hz, J2′ ,3′ ) 5.5
Hz, J2′ -2′ OH ) 5.9 Hz), 4.21 (ddd, 1H, H-3′ , J2′ ,3′ ) 5.5 Hz, J3′ ,4′ )
5.2 Hz, J3′ -3′ OH ) 5.7 Hz), 3.94-4.01 (m, 1H, H-4′ ), 2.94 (d, 1H,
N(CH3)-CH2, J ) 15.7 Hz), 2.88 (d, 1H, N(CH3)-CH2, J ) 15.7
Hz), 2.75-2.80 (m, 1H, 5′ -CH2), 2.63-2.70 (m, 1H, 5′ -CH2), 2.53
(s, 3H, 8-CH3), 2.23 (s, 3H, N-CH3). 1H NMR (D2O) δ 8.40 (s,
1H, H-2), 6.08 (d, 1H, H-1′ , J1′ ,2′ ) 4.8 Hz), 5.01 (t, 1H, H-2′ , J2′ ,3′
) 5.2 Hz), 4.60 (t, 1H, H-3′ , J3′ ,4′ ) 4.9 Hz), 4.50-4.59 (m, 1H,
H-4′ ), 4.03-4.17 (m, 2H, NH2CO-CH2), 3.82-3.92 (m, 1H, 5′ -
CH2), 3.68-3.76 (m, 1H, 5′ -CH2), 3.03 (s, 3H, N-CH3), 2.70 (s,
3H, 8-CH3). UV λmax, nm, pH 1, 259 (ε 15900), pH 7, 259.7 (ε
16100), pH 13, 260.2 (ε 16100). Anal. (C14H21N7O4·1.45-
H2SO4·0.2C2H5OH·1.3H2O) C, H, N, S.
5′ -[(2-Carboethoxyethyl)methylamino]-5′ -deoxyadenosine (17g).
The general procedure previously described for 17a was used to
prepare 17g using 9h
53 (400 mg, 1.42 mmol), ethyl 3-chloropro-
pionate (214 mg, 1.56 mmol), DIEA (92 mg, 0.12 mL, 0.71 mmol),
and DMF (5 mL). The reaction mixture was heated at 60 °C for
two days. The product was puriﬁed by column chromatography
(7:1 chloroform:methanol) to give a solid: yield 102 mg (19%).
MS m/z 381 (M + H)+.
5′ -Deoxy-5′ -[(2-carboethoxyethyl)methylamino]-2′ ,3′ -O-isopro-
pylideneadenosine (17h). To compound 9g (380 mg, 1.18 mmol)
in anhydrous CH3CN (5 mL) was added ethyl 3-chloropropionate
(195 mg, 0.18 mL, 1.42 mmol) and diisopropylethylamine (153
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75-80 °C for 72 h under nitrogen. The reaction mixture was
evaporated to dryness, and the residue was puriﬁed by column
chromatography (silica gel 230-400 mesh, elution with 9:1
methylene chloride:methanol) to yield 260 mg (52%), MS: m/z 421
(M + H)+.
5′ -[(2-Carboxamidoethyl)methylamino]-5′ -deoxy-2′ ,3′ -O-isopro-
pylideneadenosine (17i). A mixture of 17h (80 mg, 0.19 mmol) in
saturated methanolic ammonia (15 mL) was stirred for 12 days at
room temperature. The resulting solution was concentrated to
dryness, and the residue was puriﬁed by column chromatography
(elution with 9:1:0.1 methylene chloride:methanol:NH4OH) to yield
40 mg (55%). MS: m/z 392 (M + H)+.
5′ -[(2-Carboxamidoethyl)methylamino]-5′ -deoxyadenosine sul-
fate (1.9:1 salt) (17j). Compound 17i (20 mg) was dissolved in 1 N
H2SO4 (2 mL) and the solution was stirred at room temperature
for 36 h. The reaction mixture was concentrated to 0.5 mL, absolute
ethanol (3 mL) was added to the solution to produce a slight
turbidity, and the mixture was chilled at 0 °C. The solid was ﬁltered,
washed with ethanol, and dried under high vacuum: yield 15 mg
(51%). MS: m/z 352 (M + H)+. 1H NMR (DMSO-d6) δ 8.64 (s,
1H, H-8), 8.43 (s, 1H, H-2), 7.59 (bs, 1H, NH2), 7.17 (bs, 1H,
NH2), 6.02 (bdd, 1H, H-1′ , J1′ ,2′ ) 3.4 Hz), 4.65 (t, 1H, H-2′ , J2′ ,3′
) 6.4 Hz), 4.17-4.21 (bm, 1H, H-3′ ), 3.34-3.42 (bm, 1H, H-4′ ),
3.52-3.67 (bm, 4H, 5′ -CH2, N(CH3)-CH2), 2.80 (bs, 3H, N-CH3),
2.54-2.60 (bm, 2H, CO-CH2). UV λmax, nm, pH 1, 256.3 (ε 15200),
pH 7, 258.5 (ε 15400), pH 13, 259.6 (ε 16100). Anal.
(C14H21N7O4·1.9H2SO4·1.6H2O) C, H, N, S.
5′ -Deoxy-5′ -[(2-hydrazinocarbonylethyl)methylamino]-8-methyl-
adenosine sulfate (2:1 salt) (17k). Compound 17a (115 mg, 0.29
mmol) was dissolved in 10 mL of anhydrous ethanol, and hydrazine
monohydrate (73 mg, 0.07 mL, 1.46 mmol) was added to the
solution. The reaction mixture was heated to reﬂux overnight.
Hydrazine monohydrate (0.07 mL) was added again, and heating
was continued overnight. The resulting solution was evaporated to
dryness. The crude product was puriﬁed by column chromatography
(4:1:0.5 chloroform:methanol:NH4OH), affording a sticky solid. The
product was dissolved in 8 mL of EtOH, and2NH 2SO4 was added
dropwise. The salt that was precipitated out was ﬁltered and washed
with EtOH. This salt, which was hygroscopic in nature, was
dissolved in water (2 mL) and lyophilized to give a white solid:
yield 71 mg (65%). MS: m/z 381 (M + H)+. 1H NMR (D2O) δ
8.44 (s, 1H, H-2), 6.09 (d, 1H, H-1′ , J1′ ,2′ ) 5.6 Hz), 5.10 (dd, 1H,
H-2′ , J2′ ,3′ ) 4.5 Hz), 4.53-4.62 (bm, 2H, H-3′ , H-4′ ), 3.86-3.94
(m, 1H, 5′ -CH2), 3.52-3.66 (m, 3H, 5′ -CH2, N(CH3)-CH2), 2.95
(s, 3H, N-CH3), 2.86 (t, 2H, NHCO-CH2), 2.70 (s, 3H, 8-CH3).
UV λmax, nm, pH 1, 258.4 (ε 15000), pH 7, 259.3 (ε 15200), pH
13, 260.4 (ε 15700). Anal. (C15H24N8O4·2.0 H2SO4·2.7H2O) C,
H, N, S.
5′ -Deoxy-5′ -[(2-hydrazinocarbonylethyl)methylamino]-adenos-
ine sulfate (2:1 salt) (17l). The procedure was the same as reported
above for 17k using 17g (95 mg, 0.25 mmol) and hydrazine
monohydrate (63 mg, 0.06 mL, 1.25 mmol): yield 39 mg (43%).
MS: m/z 367 (M + H)+. 1H NMR (D2O) δ 8.47 (s, 1H, H-8), 8.45
(s, 1H, H-2), 6.17 (d, 1H, H-1′ , J1′ ,2′ ) 4.7 Hz), 4.90 (dd, 1H, H-2′ ,
J2′ ,3′ ) 5.2 Hz), 4.56-4.60 (bm, 1H, H-4′ ), 4.48 (dd, 1H, H-3′ ,
J3′ ,4′ ) 5.0 Hz), 3.82 (dd, 1H, 5′ -CH2), 3.66 (dd, 1H, 5′ -CH2), 3.59
(bt, 2H, N(CH3)-CH2), 2.97 (s, 3H, N-CH3), 2.86 (t, 2H, NHCO-
CH2). UV λmax, nm, pH 1, 256.8 (ε 16600), pH 7, 258.5 (ε 16800),
pH 13, 259.5 (ε 17,600). Anal. (C14H22N8O4·2.0 H2SO4·2.0H2O)
C, H, N.
5′ -Deoxy-5′ -[(hydrazinocarbonylmethyl)methylamino]-8-methyl-
adenosine (17m). The same procedure used to prepare 17k was
used to prepare 17m using 17c (167 mg, 0.44 mmol) and hydrazine
monohydrate (109 mg, 0.11 mL, 2.18 mmol). After the column it
yielded a white solid: yield 154 mg (96%). MS: m/z 367 (M +
H)+. 1H NMR (DMSO-d6) δ 8.75 (bs, 1H, NH), 8.09 (s, 1H, H-2),
7.10 (bs, 2H, NH-NH2), 5.74 (d, 1H, H-1′ , J1′ ,2′ ) 5.2 Hz), 5.31 (d,
1H, OH-2′ , J2′ -2′ OH ) 6.0 Hz), 5.18 (d, 1H, OH-3′ , J3′ -3′ OH ) 5.6
Hz), 5.0 (ddd, 1H, H-2′ , J1′ ,2′ ) 5.2 Hz, J2′ ,3′ ) 5.7 Hz, J2′ -2′ OH )
6.0 Hz), 4.19 (ddd, 1H, H-3′ , J2′ ,3′ ) 5.7 Hz, J3′ ,4′ ) 4.9 Hz, J3′ -3′ OH
) 5.6 Hz), 3.94-3.99 (m, 1H, H-4′ ), 3.01 (d, 1H, CO-CHa Hb, J
) 15.2 Hz), 2.95 (d, 1H, CO-CHa Hb, J ) 15.2 Hz), 2.78 (dd, 1H,
5′ -CH2), 2.66 (dd, 1H, 5′ -CH2), 2.53 (s, 3H, 8-CH3), 2.22 (s, 3H,
N-CH3). UV λmax, nm, pH 1, 258.9 (ε 15300), pH 7, 259.3 (ε
15600), pH 13, 260.1 (ε 16100). Anal. (C14H22N8O4·0.2
CH3OH·0.4H2O) C, H, N.
5′ -[(3-Aminopropyl)methylamino]-5′ -deoxy-8-(methylamino)ad-
enosine sulfate (2.4:1 salt) (18a) and 5′ -deoxy-8-(methylamino)-5′ -
(3-methylaminopropylamino)adenosine sulfate (2.4:1 salt) (19a).
A solution of 8c (175 mg, 0.55 mmol) in 2 mL of N-methyl-1,3-
propanediamine was stirred for four days at ambient temperature.
The mixture was poured into diethyl ether (20 mL). Decantation
of the ether layer left an oil, which was puriﬁed by column
chromatography. The column was eluted with 4:1:0.5 chloroform:
methanol:NH4OH to afford two isomers. These separated isomers
were dissolved in 6 mL of EtOH and 5 mL of EtOH respectively,
a n d2NH 2SO4 was added dropwise. The sulfate salts that
precipitated out were ﬁltered and washed with EtOH. These salts,
which were hygroscopic in nature, were dissolved in water (2 mL)
and lyophilized to give white solids: 18a: yield 50 mg (15%). MS:
m/z 367 (M + H)+. 1H NMR (DMSO-d6) δ 7.91 (s, 1H, H-2), 6.90
(bs, 1H, 8CH3-NH), 6.49 (bs, 2H, 6-NH2), 5.70 (d, 1H, H-1′ , J1′ ,2′
) 4.8 Hz), 4.92 (t, 1H, H-2′ , J2′ ,3′ ) 5.5 Hz), 4.17 (t, 1H, H-3′ ,
J3′ ,4′ ) 5.2 Hz), 3.89-3.96 (bm, 1H, H-4′ ), 2.89 (s, 3H, 8NH-CH3),
2.53-2.70 (m, 4H, NH2-CH2, 5′ -CH2), 2.38 (t, 2H, N(CH3)-CH2),
2.17 (s, 3H, N-CH3), 1.48-1.60 (m, 2H, NH2CH2-CH2). 1H NMR
(D2O) δ 8.28 (s, 1H, H-2), 5.87 (d, 1H, H-1′ , J1′ ,2′ ) 5.1 Hz), 5.18
(t, 1H, H-2′ , J2′ ,3′ ) 5.1 Hz), 4.54 (t, 1H, H-3′ , J3′ ,4′ ) 5.1 Hz),
4.46-4.51 (m, 1H, H-4′ ), 3.01-3.82 (bm, 6H, 5′ -CH2, NH2-CH2,
N(CH3)-CH2), 3.05 (s, 3H, 8NH-CH3), 2.94 (s, 3H, N-CH3),
2.05-2.18 (bm, 2H, NH2CH2-CH2). UV λmax, nm, pH 1, 275.5 (ε
14500), pH 7, 275 (ε 17200), pH 13, 277 (ε 17500). Anal.
(C15H26N8O3·2.4H2SO4·0.2C2H5OH) C, H, N. 19a: yield 29 mg
(7%). MS: m/z 367 (M + H)+. 1H NMR (DMSO-d6) δ 7.96 (s,
1H, H-2), 7.0 (bs, 1H, 8CH3-NH), 6.57 (bs, 2H, 6-NH2), 5.80 (d,
1H, H-1′ , J1′ ,2′ ) 5.5 Hz), 4.97 (t, 1H, H-2′ , J2′ ,3′ ) 5.5 Hz), 5.4
(bs, 2H, 2′ ,3 ′ -OH’s), 4.33 (t, 1H, H-3′ , J3′ ,4′ ) 3.7 Hz), 4.17-4.24
(bm, 1H, H-4′ ), 3.20-3.50 (m, 2H, 5′ -CH2), 3.05-3.85 (m, 4H,
NH-CH2), 2.88 (s, 3H, 8NH-CH3), 2.49 (s, 3H, NH-CH3), 1.85-2.0
(bm, 2H, NHCH2-CH2). 1H NMR (D2O) δ 8.27 (s, 1H, H-2), 5.86
(d, 1H, H-1′ , J1′ ,2′ ) 5.2 Hz), 5.16 (t, 1H, H-2′ , J2′ ,3′ ) 5.5 Hz),
4.55 (t, 1H, H-3′ , J3′ ,4′ ) 4.5 Hz), 4.36-4.44 (m, 1H, H-4′ ),
3.47-3.69 (m, 2H, 5′ -CH2), 3.22 (t, 2H, NH-CH2), 3.10 (t, 2H,
CH3NH-CH2), 3.05 (s, 3H, 8NH-CH3), 2.71 (s, 3H, NH-CH3),
2.04-2.18 (bm, 2H, NHCH2-CH2). UV λmax, nm, pH 1, 274.1 (ε
14300), pH 7, 276 (ε 17100), pH 13, 277.1 (ε 18700). Anal.
(C15H26N8O3·2.4H2SO4·0.2C2H5OH) C, H, N.
5′ -[(3-Aminopropyl)methylamino]-5′ -deoxy-8-phenyladenos-
ine sulfate (2.2:1 salt) (18b) and 5′ -deoxy-5′ -(3-methylaminopro-
pylamino)-8-phenyladenosine sulfate (1.7:1 salt) (19b). The same
procedure as described above for 18a was used to prepare 18b and
19b from 8d (200 mg, 0.55 mmol), and N-methyl-1,3-propanedi-
amine (3 mL) except in this case, after one day of stirring at room
temperature, the reaction mixture was heated at 65 °C for two days.
The column was eluted with 4:1:0.2 chloroform:methanol:NH4OH.
After the same work up, two isomers were obtained. 18b: yield
124 mg (34%). MS: m/z 414 (M + H)+. 1H NMR (DMSO-d6) δ
8.38 (s, 1H, H-2), 7.61-7.84 (m, 7H, 8-phenyl, 6-NH2), 5.88 (d,
1H, H-1′ , J1′ ,2′ ) 6.3 Hz), 5.17-5.30 (bm, 1H, H-2′ ), 4.34-4.38
(bm, 1H, H-3′ ), 4.25-4.31 (bm, 1H, H-4′ ), 3.10-3.85 (bm, 4H,
N(CH3)-CH2, 5′ -CH2), 2.80-2.94 (m, 2H, NH2-CH2), 2.78 (s, 3H,
N-CH3), 1.81-2.0 (bm, 2H, NH2CH2-CH2). UV λmax, nm, pH 1,
274.2 (ε 20500), pH 7, 275.8 (ε 16300), pH 13, 274.5 (ε 16400).
Anal. (C20H27N7O3·2.2H2SO4·0.1C2H5OH·2.5H2O) C, H, N, S.
19b: yield 151 mg (42%). MS: m/z 414 (M + H)+. 1H NMR
(DMSO-d6) δ 8.23 (s, 1H, H-2), 7.0-7.74 (m, 2H, 8-phenyl o-H’s),
7.60-7.65 (m, 3H, 8-phenyl m- and p-H’s), 7.46 (bs, 2H, 6-NH2),
5.80 (d, 1H, H-1′ , J1′ ,2′ ) 6.2 Hz), 5.25 (t, 1H, H-2′ , J2′ ,3′ ) 4.9
Hz), 5.5-6.0 (m, 2H, NH’s), 4.29-4.35 (bm, 1H, H-3′ ), 4.12-4.20
(m, 1H, H-4′ ), 3.40-3.47 (m, 1H, 5′ -CH2), 3.19-3.25 (m, 1H, 5′ -
CH2), 2.94 (m, 4H, NH-CH2,C H 3NH-CH2), 2.54 (s, 3H, NH-CH3),
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20600), pH 7, 274.9 (ε 16200), pH 13, 274.9 (ε 16,300). Anal.
(C20H27N7O3·1.7H2SO4·0.05C2H5OH·3.3H2O) C, H, N, S.
5′ -[(3-Aminopropyl)methylamino]-5′ -deoxy-2′ ,3′ -O-isopropylide-
neadenosine (18c). A mixture of 8h
42 (1.0 g, 2.60 mmol) and
N-methyl-1,3-propanediamine (1.35 mL, 13.0 mmol) was stirred
overnight under an argon atmosphere. The reaction mixture was
concentrated to dryness, and the crude product was puriﬁed by
column chromatography using chloroform:methanol:NH4OH (6:1:
0.1) as eluent to give a semisolid. This material was dissolved in
3 mL of water and lyophilized: yield 361 mg (37%). MS: m/z 378
(M + H)+. 1H NMR (DMSO-d6) δ 8.33 (s, 1H, H-8), 8.17 (s, 1H,
H-2), 7.33 (bs, 2H, 6-NH2), 6.13 (d, 1H, H-1′ , J1′ ,2′ ) 2.3 Hz),
5.49 (dd, 1H, H-2′ , J2′ ,3′ ) 4.0 Hz), 4.94 (dd, 1H, H-3′ , J3′ ,4′ ) 2.9
Hz), 4.21-4.27 (m, 1H, H-4′ ), 2.52-2.58 (m, 2H, NH2-CH2),
2.26-2.38 (m, 4H, 5′ -CH2, N(CH3)-CH2), 2.12 (s, 3H, N-CH3),
1.53 and 1.33 (2s, 6H, C(CH3)2), 1.37-1.47 (m, 2H,
NH2CH2-CH2).
5′ -[(3-Aminopropyl)methylamino]-5′ -deoxyadenosine sulfate (2:1
salt) (18d). The procedure described for 17j was used to prepare
18d from 18c (200 mg, 0.53 mmol): yield 121 mg (41%). MS: m/z
338 (M + H)+. 1H NMR (DMSO-d6) δ 8.47 (bs, 1H, H-8), 8.29
(bs, 1H, H-2), 7.0-10.0 (broad peaks, NH2s + H2SO4), 5.97 (d,
1H, H-1′ , J1′ ,2′ ) 4.7 Hz), 5.70 (bs, 1H, 2′ -OH), 5.56 (bs, 1H, 3′ -
OH), 4.72 (bt, 1H, H-2′ ), 4.30 (bm, 1H, H-4′ ), 4.21 (bt, 1H, H-3′ ),
3.30-3.70 (bm, 2H, 5′ -CH2), 3.08 (bs, 2H, N(CH3)-CH2), 2.83 (bm,
2H, NH2-CH2), 2.70 (bs, 3H, N-CH3), 1.84-1.92 (m, 2H,
NH2CH2-CH2). UV λmax, nm, pH 1, 257(ε 14700), pH 7, 259.2 (ε
15000), pH 13, 260 (ε 15300). Anal. (C14H23N7O3·2.0H2SO4·
0.25C2H5OH·0.7H2O) C, H, N.
5′ -[(2-Aminoethyl)methylamino]-5′ -deoxyadenosine (18e) and
5′ -deoxy-5′ -(2-methylaminoethylamino)adenosine (19c). A mixture
of 8g
32 (1.0 g, 3.5 mmol) and N-methylethylenediamine (8 mL)
was stirred at room temperature for 12 days. The reaction mixture
was poured into diethyl ether (50 mL). The ether layer was decanted
and the resulting syrup was puriﬁed by column chromatography
(silica gel 230-400 mesh, elution with 4:1:0.5 chloroform:
methanol:NH4OH) to give the two isomers. 18e: yield 576 mg
(51%). MS: m/z 324 (M + H)+. 1H NMR (DMSO-d6) δ 8.35 (s,
1H, H-8), 8.15 (s, 1H, H-2), 7.27 (bs, 2H, 6-NH2), 5.85 (d, 1H,
H-1′ , J1′ ,2′ ) 5.3 Hz), 4.64 (dd, 1H, H-2′ , J2′ ,3′ ) 5.3 Hz), 4.11 (dd,
1H, H-3′ , J3′ ,4′ ) 4.3 Hz), 3.95-4.0 (m, 1H, H-4′ ), 2.90-3.60 (bs,
4H, 2′ ,3 ′ -OHs + NHs), 2.70 (dd, 1H, 5′ -CH2), 2.50-2.60 (bm,
3H, 5′ -CH2, N(CH3)-CH2), 2.36 (t, 2H, NH2-CH2), 2.19 (s, 3H,
N-CH3). UV λmax, nm, pH 1, 256.9 (ε 14100), pH 7, 259.5 (ε
14700), pH 13, 259.2 (ε 15300). Anal. (C13H21N7O3·
0.25CHCl3·0.5H2O) C, H, N. 19c: yield 323 mg (29%). MS: m/z
324 (M + H)+. 1H NMR (DMSO-d6) δ 8.35 (s, 1H, H-8), 8.14 (s,
1H, H-2), 7.28 (bs, 2H, 6-NH2), 5.84 (d, 1H, H-1′ , J1′ ,2′ ) 5.9 Hz),
4.69 (dd, 1H, H-2′ , J2′ ,3′ ) 5.3 Hz), 4.12 (dd, 1H, H-3′ , J3′ ,4′ ) 3.5
Hz), 3.94-3.99 (m, 1H, H-4′ ), 2.90-3.60 (bs, 4H, 2′ ,3 ′ -OHs +
NHs), 2.80 (dd, 1H, 5′ -CH2), 2.73 (dd, 1H, 5′ -CH2), 2.50-2.62
(bm, 4H, NHCH3-CH2, NH-CH2), 2.25 (s, 3H, NH-CH3). UV λmax,
nm, pH 1, 256.4 (ε 13900), pH 7, 259 (ε 13900), pH 13, 259.8 (ε
14000). Anal. (C13H21N7O3·0.05CH3OH·0.1H2O) C, H, N.
5′ -[(2-Aminoethyl)methylamino]-5′ -deoxy-8-methyladenosine (18f)
and 5′-deoxy-8-methyl-5′-(2-methylaminoethylamino)adenosine (19d).
The procedure described above for 18e/19c was used to prepare
18f/19d from 8a (300 mg, 1.0 mmol) and N-methylethylenediamine
(3 mL). 18f: yield ( 69 mg (18.3%). MS: m/z 338 (M + H)+. 1H
NMR (DMSO-d6) δ 8.08 (s, 1H, H-2), 7.11 (bs, 2H, 6-NH2), 5.74
(d, 1H, H-1′ , J1′ ,2′ ) 5.4 Hz), 5.31 (bs, 1H, 2′ -OH), 5.04 (dd, 1H,
H-2′ , J2′ ,3′ ) 5.6 Hz), 4.17 (dd, 1H, H-3′ , J3′ ,4′ ) 4.5 Hz), 4.08 (bs,
1H, 3′ -OH), 3.93-3.98 (m, 1H, H-4′ ), 2.70 (dd, 1H, 5′ -CH2),
2.53-2.57 (bm, 3H, 5′ -CH2, N(CH3)-CH2), 2.53 (s, 3H, 8-CH3),
2.30-2.35 (m, 2H, NH2-CH2), 2.16 (s, 3H, N-CH3). UV λmax,n m ,
pH 1, 258.5 (ε 15600), pH 7, 259.1 (ε 16000), pH 13, 260 (ε 16200).
Anal. (C14H23N7O3·0.5CH3OH·0.3H2O) C, H, N. 19d: yield ( 58
mg (15.4%). MS: m/z 338 (M + H)+. 1H NMR (DMSO-d6) δ 8.07
(s, 1H, H-2), 7.12 (bs, 2H, 6-NH2), 5.72 (d, 1H, H-1′ , J1′ ,2′ ) 6.4
Hz), 5.27 (bs, 1H, 2′ -OH), 5.02 (dd, 1H, H-2′ , J2′ ,3′ ) 5.4 Hz),
4.17 (dd, 1H, H-3′ , J3′ ,4′ ) 3.1 Hz), 3.94-3.99 (m, 1H, H-4′ ), 2.80
(dd, 1H, 5′ -CH2), 2.74 (dd, 1H, 5′ -CH2), 2.54-2.63 (bm, 4H,
NHCH3-CH2, NH-CH2), 2.54 (s, 3H, 8-CH3), 2.24 (s, 3H, NH-
CH3). UV λmax, nm, pH 1, 258.4 (ε 15400), pH 7, 259.5 (ε 15400),
pH 13, 260 (ε 15900). Anal. (C14H23N7O3·0.4CH3OH·0.7H2O) C,
H, N.
5′ -Deoxy-2′ ,3′ -O-isopropylidene-5′ -[(3-phthalimidopropyl)methyl-
amino]-8-methyladenosine (20a). To a cold solution of compound
7e (500 mg, 1.5 mmol) in anhydrous pyridine (2 mL) was added
methanesulfonyl chloride (196 mg, 0.13 mL, 1.7 mmol) and the
solution was stirred for 2 h at 0 °C. The reaction mixture was
concentrated to dryness to afford crude 8e. Methylamine (33%
solution in EtOH, 12 mL) was added to this crude mixture, and
the solution was stirred for three days at room temperature. The
reaction mixture was evaporated to dryness. The resulting crude
9e was dissolved in anhydrous DMF (3 mL), DIEA (0.07 mL),
and N-(3-bromopropyl)phthalimide (502 mg, 1.87 mmol) were
added, and the reaction mixture was heated overnight at 60 °C.
The solution was evaporated to dryness, and the residue was
dissolved in CHCl3 (10 mL), washed with water, dried over Na2SO4,
and concentrated to dryness. The resulting syrup was puriﬁed by
column chromatography. The column was eluted with 97:3 chlo-
roform:methanol to yield 108 mg (13%). MS m/z 522 (M + H)+.
1H NMR (CDCl3) δ 8.26 (s, 1H, H-2), 7.82-7.86 (m, 2H,
phthalimido aromatic H’s), 7.69-7.73 (m, 2H, phthalimido aromatic
H’s), 5.98 (d, 1H, H-1′ , J1′ ,2′ ) 1.8 Hz), 5.76 (dd, 1H, H-2′ , J1′ ,2′ )
1.8 Hz, J2′ ,3′ ) 6.5 Hz), 5.38 (bs, 2H, 6-NH2), 5.10 (dd, 1H, H-3′ ,
J2′ ,3′ ) 6.5 Hz, J3′ ,4′ ) 3.5 Hz), 4.26-4.32 (m, 1H, H-4′ ), 3.60-3.76
(m, 2H, N-CH2), 2.64 (s, 3H, 8-CH3), 2.58-2.63 (m, 1H, 5′ -CH2),
241-2.48 (m, 1H, 5′ -CH2), 2.38 (t, 2H, N(CH3)-CH2), 2.21 (s, 3H,
N-CH3), 1.68-1.80 (m, 2H, NCH2-CH2), 1.61 and 1.40 (2s, 6H,
C(CH3)2).
5′ -Deoxy-2′ ,3′ -O-isopropylidene-5′ -[(3-phthalimidopropyl)methyl-
amino]-8-ethyladenosine (20b). The same procedure as described
for 20a was used to prepare 20b from 7f (600 mg, 1.78 mmol),
MsCl (225 mg,0.15 mL, 1.96 mmol), methylamine (12 mL), and
N-(3-bromopropyl)phthalimide (553 mg, 2.06 mmol): yield 81 mg
(8.5%). MS: m/z 536 (M + H)+. 1H NMR (CDCl3) δ 8.26 (s, 1H,
H-2), 7.81-7.86 (m, 2H, phthalimido aromatic H’s), 7.67-7.72
(m, 2H, phthalimido aromatic H’s), 5.98 (d, 1H, H-1′ , J1′ ,2′ ) 2.0
Hz), 5.75 (dd, 1H, H-2′ , J1′ ,2′ ) 2.0 Hz, J2′ ,3′ ) 6.5 Hz), 5.37 (bs,
2H, 6-NH2), 5.12 (dd, 1H, H-3′ , J2′ ,3′ ) 6.5 Hz, J3′ ,4′ ) 3.5 Hz),
4.25-4.33 (m, 1H, H-4′ ), 3.61-3.75 (m, 2H, N-CH2), 2.94 (q, 2H,
CH2 of 8-Et), 2.62-2.68 (m, 1H, 5′ -CH2), 243-2.49 (m, 1H, 5′ -
CH2), 2.38 (bt, 2H, N(CH3)-CH2), 2.22 (s, 3H, N-CH3), 1.70-1.80
(m, 2H, NCH2-CH2), 1.60 and 1.40 (2s, 6H, C(CH3)2), 1.42 (t,
3H, CH3 of 8-Et).
5′ -Deoxy-2′ ,3′ -O-isopropylidene-5′ -[(3-aminopropyl)methylamino]-
8-methyladenosine (21a). To a boiling solution of 20a (100 mg,
0.19 mmol) in 3 mL of ethanol was added hydrazine monohydrate
(50 mg, 0.048 mL, 0.99 mmol) and the solution was heated to reﬂux
for 1 h. The reaction mixture was cooled down to room temperature,
and the solid was ﬁltered and washed with ethanol. The ﬁltrate
was evaporated to dryness. This crude product was puriﬁed by
column chromatography using chloroform:methanol:NH4OH (7:1:
0.2) for elution: yield 69 mg (92%). MS: m/z 392 (M + H)+. 1H
NMR (DMSO-d6) δ 8.12 (s, 1H, H-2), 7.18 (bs, 2H, 6-NH2), 6.06
(d, 1H, H-1′ , J1′ ,2′ ) 1.9 Hz), 5.79 (dd, 1H, H-2′ , J1′ ,2′ ) 1.9 Hz,
J2′ ,3′ ) 6.3 Hz), 5.0 (dd, 1H, H-3′ , J2′ ,3′ ) 6.3 Hz, J3′ ,4′ ) 3.1 Hz),
4.15-4.21 (m, 1H, H-4′ ), 2.56 (s, 3H, 8-CH3), 2.40-2.50 (m, 2H,
N(CH3)-CH2), 2.13-2.31 (bm, 4H, NH2-CH2, 5′ -CH2), 2.07 (s,
3H, N-CH3), 1.53 and 1.33 (2s, 6H, C(CH3)2), 1.22-1.32 (m, 2H,
NH2CH2-CH2).
5′ -Deoxy-2′ ,3′ -O-isopropylidene-5′ -[(3-aminopropyl)methylamino]-
8-ethyladenosine (21b). Compound 21b was prepared by the same
procedure as reported for 21a using 20b (76 mg, 0.14 mmol) and
hydrazine monohydrate (38 mg, 0.036 mL, 0.76 mmol): yield 47
mg (82%). MS: m/z 406 (M + H)+. 1H NMR (DMSO-d6) δ 8.12
(s, 1H, H-2), 7.16 (bs, 2H, 6-NH2), 6.03 (d, 1H, H-1′ , J1′ ,2′ ) 2.0
Hz), 5.76 (dd, 1H, H-2′ , J1′ ,2′ ) 2.0 Hz, J2′ ,3′ ) 6.4 Hz), 5.01 (dd,
1H, H-3′ , J2′ ,3′ ) 6.4 Hz, J3′ ,4′ ) 3.0 Hz), 4.15-4.22 (m, 1H, H-4′ ),
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2.13-2.34 (m, 4H, N(CH3)-CH2,N H 2-CH2), 2.08 (s, 3H, N-CH3),
1.53 and 1.33 (2s, 6H, C(CH3)2), 1.22-1.39 (m, 2H,
NH2CH2-CH2), 1.31 (t, 3H, CH3 of 8-Et).
5′ -[(3-Aminopropyl)methylamino]-5′ -deoxy-8-methyladenos-
ine sulfate (2:1 salt) (21c). Compound 21a (66 mg, 0.168 mmol)
was dissolved in 2 mL of1NH 2SO4 and stirred overnight. To this
solution was added ethanol (10 mL), causing a ﬁne solid to separate.
The solvent was decanted, the compound was dissolved in water
(1 mL), and 15 mL of ethanol was added. The resulting solid was
dissolved in water (2 mL) and lyophilized to give a white solid:
yield 66 mg (67%). MS: m/z 352 (M + H)+. 1H NMR (DMSO-d6)
δ 8.16 (s, 1H, H-2), 7.74 (bs, 2H, CH2-NH2), 7.24 (bs, 2H, 6-NH2),
5.84 (d, 1H, H-1′ , J1′ ,2′ ) 6.0 Hz), 5.62 (bs, 2H, 2′ ,3 ′ -OH’s), 4.98
(t, 1H, H-2′ , J2′ ,3′ ) 4.4 Hz), 4.29-4.36 (bm, 1H, H-4′ ), 4.23 (t,
1H, H-3′ ), 3.40-3.68 (bm, 2H, 5′ -CH2), 2.99-3.19 (bm, 2H,
N(CH3)-CH2), 2.83 (t, 2H, NH2-CH2), 2.70 (bs, 3H, N-CH3), 2.55
(s, 3H, 8-CH3), 1.80-1.93 (m, 2H, NH2CH2-CH2). UV λmax, nm,
pH 1, 258.7 (ε 14900), pH 7, 259.5 (ε 15100), pH 13, 260.7 (ε
15300). Anal. (C15H25N7O3·2.0H2SO4·2.5H2O) C, H, N, S.
5′ -[(3-Aminopropyl)methylamino]-5′ -deoxy-8-ethyladenosine sul-
fate (2.5:1 salt) (21d). The procedure described for 21c was used
to prepare 21d from 21b (44 mg, 0.108 mmol). In this case after
the addition of EtOH a ﬁne solid came out, which was collected
by centrifugation. It was then dissolved in water (2 mL) and
lyophilized: yield 30 mg (69%). MS: m/z 366 (M + H)+. 1H NMR
(DMSO-d6) δ; 8.15 (s, 1H, H-2), 7.68 (bs, 2H, CH2-NH2), 7.21
(bs, 2H, 6-NH2), 5.82 (d, 1H, H-1′ , J1′ ,2′ ) 6.0 Hz), 5.61 (bs, 2H,
2′ ,3 ′ -OH’s), 5.04 (t, 1H, H-2′ ), 4.19-4.27 (bm, 2H, H-3′ ,4 ′ ),
3.22-3.43 (bm, 4H, 5′ -CH2, N(CH3)-CH2), 2.90 (q, 2H, 8CH2CH3),
2.81 (t, 2H, NH2-CH2), 2.50 (bs, 3H, N-CH3), 1.73-1.88 (bm,
2H, NH2CH2-CH2), 1.32 (t, 3H, 8CH2CH3). UV λmax, nm, pH 1,
259.3 (ε 15100), pH 7, 260.5 (ε 15100), pH 13, 260.3 (ε 15100).
Anal. (C16H27N7O3·2.5H2SO4·2.5H2O) C, H, N.
5′ -Deoxy 5′ -[(2-guanidinoethyl)methylamino]adenosine (22a). To
a stirred solution of 18e (218 mg, 0.67 mmol) and 1H-pyrazole-
1-carboxamidine hydrochloride
30 (196 mg, 1.34 mmol) in anhy-
drous DMF (5 mL) was added DIEA (479 mg, 0.65 mL, 3.7 mmol)
under nitrogen at 5 °C. Stirring was continued at room temperature
overnight. The reaction mixture was concentrated to dryness, and
the product was puriﬁed by column chromatography (silica gel
230-400 mesh, elution with 4:1:0.3 chloroform:methanol:NH4OH)
to afford 219 mg (89%). MS: m/z 366 (M + H)+. 1H NMR (DMSO-
d6) δ 8.34 (s, 1H, H-8), 8.15 (s, 1H, H-2), 7.48, 7.37, 7.28 (bs,
NHs), 5.87 (d, 1H, H-1′ , J1′ ,2′ ) 5.2 Hz), 5.50 (d, 1H, 2′ -OH, J2′ -2′ OH
) 5.7 Hz), 5.28 (d, 1H, 3′ -OH, J3′ -3′ OH ) 4.5 Hz), 4.65 (ddd, 1H,
H-2′ , J1′ ,2′ ) 5.2 Hz, J2′ ,3′ ) 5.1 Hz, J2′ -2′ OH ) 5.7 Hz), 4.12 (ddd,
1H, H-3′ , J2′ ,3′ ) 5.1 Hz, J3′ ,4′ ) 4.6 Hz, J3′ -3′ OH ) 4.5 Hz), 4.0-4.10
(bm, 1H, H-4′ ), 3.30-3.50 (bm, 2H, 5′ -CH2), 3.12-3.28 (bm, 2H,
NH-CH2), 2.55-2.65 (bm, 2H, N(CH3)-CH2), 2.25 (bs, 3H, N-CH3).
UV λmax, nm, pH 1, 256.3 (ε 10900), pH 7, 259 (ε 11300), pH 13,
259 (ε 11000). Anal. (C14H23N9O3·0.05CHCl3·3.5H2O) C, H, N.
5′ -[(2-Cyanoethyl)methylamino]-5′ -deoxyadenosine (22b). A so-
lution of 8j
54 (1.0 g, 2.37 mmol) in 10 mL of 3-(methylamino)
propionitrile was stirred at room temperature for ﬁve days. The
reaction mixture was poured into diethyl ether (50 mL). The ether
layer was decanted, and the resulting syrup was puriﬁed by column
chromatography (silica gel, elution with 7:1:0.1 chloroform:
methanol:NH4OH) to yield 685 mg (87%). MS: m/z 324 (M + H)+.
1H NMR (DMSO-d6) δ 8.34 (s, 1H, H-8), 8.15 (s, 1H, H-2), 7.29
(bs, 2H, 6-NH2), 5.87 (d, 1H, H-1′ , J1′ ,2′ ) 5.4 Hz), 5.46 (bd, 1H,
2′ -OH), 5.22 (bd, 1H, 3′ -OH), 4.65 (m, 1H, H-2′ ), 4.13 (m, 1H,
H-3′ ), 3.97-4.03 (m, 1H, H-4′ ), 2.78 (dd, 1H, 5′ -CH2), 2.58-2.68
(bm, 5H, 5′ -CH2, NC-CH2CH2), 2.24 (s, 3H, N-CH3).
5′ -Deoxy-5′ -[(2-hydroxyamidinoethyl)methylamino]adenosine
(22c). To a solution of 22b (470 mg, 1.4 mmol) in 20 mL of
anhydrous MeOH and 4 mL of anhydrous DMF under nitrogen
was added hydroxylamine hydrochloride (258 mg, 3.7 mmol) and
potassium hydroxide (206 mg, 3.7 mmol) and the resulting
suspension was stirred at room temperature for two days. The
reaction mixture was concentrated to dryness, and the crude product
was extracted with EtOAc (2 × 40 mL) and washed with brine
solution (20 mL). The organic layer was dried over Na2SO4, ﬁltered,
washed with EtOAc, and concentrated to dryness. The product was
puriﬁed by column chromatography. The column was eluted with
4:1:0.5 chloroform:methanol:NH4OH to yield 165 mg (32%). MS:
m/z 367 (M + H)+. 1H NMR (DMSO-d6) δ 8.70 (bs, 1H, NOH),
8.33 (s, 1H, H-8), 8.15 (s, 1H, H-2), 7.27 (bs, 2H, 6-NH2), 5.86 (d,
1H, H-1′ , J1′ ,2′ ) 5.3 Hz), 5.43 (d, 1H, 2′ -OH, J2′ -2′ OH ) 6.0 Hz),
5.35 (bs, 2H, C-NH2), 5.20 (d, 1H, 3′ -OH, J3′ -3′ OH ) 5.2 Hz), 4.63
(ddd, 1H, H-2′ , J1′ ,2′ ) 5.3 Hz, J2′ ,3′ ) 4.9 Hz, J2′ -2′ OH ) 6.0 Hz),
4.10 (ddd, 1H, H-3′ , J2′ ,3′ ) 4.9 Hz, J3′ ,4′ ) 3.5 Hz, J3′ -3′ OH ) 5.2
Hz), 3.96-4.0 (m, 1H, H-4′ ), 2.64-2.75 (bm, 2H, 5′ -CH2), 2.56
(t, 2H, N(CH3)-CH2), 2.20 (s, 3H, N-CH3), 2.09 (t, 2H, C-CH2).
Anal. (C14H22N8O4·1.2C2H5OH·0.2CH3OH) C, H, N.
5′ -Deoxy-5′ -(N,N-dimethylamino)-8-methyladenosine (23a). A
mixture of 8a (150 mg, 0.50 mmol) anda2Msolution of
dimethylamine in methanol (10 mL) in a steel bomb was heated
for two days at 90 °C. The reaction mixture was concentrated to
dryness and puriﬁed by column chromatography (elution with 4:1:
0.15 chloroform:methanol:NH4OH) to afford 38 mg (25%). MS
m/z 309 (M + H)+. 1H NMR (DMSO-d6) δ 8.08 (s, 1H, H-2), 7.11
(bs, 2H, 6-NH2), 5.74 (d, 1H, H-1′ , J1′ ,2′ ) 5.5 Hz), 5.31 (d, 1H,
OH-2′ , J2′ -2′ OH ) 5.9 Hz), 5.18 (d, 1H, OH-3′ , J3′ -3′ OH ) 5.4 Hz),
5.03 (ddd, 1H, H-2′ , J1′ ,2′ ) 5.5 Hz, J2′ ,3′ ) 4.6 Hz, J2′ -2′ OH ) 5.9
Hz), 4.15 (ddd, 1H, H-3′ , J2′ ,3′ ) 4.6 Hz, J3′ ,4′ ) 5.5 Hz, J3′ -3′ OH )
5.4 Hz), 3.91-3.96 (m, 1H, H-4′ ), 2.55-2.61 (m, 1H, 5′ -CH2),
2.53 (s, 3H, 8-CH3), 2.42-2.48 (m, 1H, 5′ -CH2), 2.14 (bs, 6H,
N-(CH3)2). UV λmax, nm, pH 1, 258.5 (ε 15300), pH 7, 259.3 (ε
15300), pH 13, 260.1 (ε 15500). Anal. (C13H20N6O3·
0.35CHCl3·0.5C2H5OH) C, H, N.
5′ -Deoxy-5′ -(N,N-dimethylamino)adenosine (23b). Compound
23b was prepared by the same procedure as described for the
preparation of 23a using 8g
32 (500 mg, 1.75 mmol) anda2M
solution of dimethylamine in methanol (20 mL): yield 238 mg
(46%). MS m/z 295 (M + H)+. 1H NMR (DMSO-d6) δ 8.33 (s,
1H, H-8), 8.15 (s, 1H, H-2), 7.29 (bs, 2H, 6-NH2), 5.86 (d, 1H,
H-1′ , J1′ ,2′ ) 5.4 Hz), 5.45 (d, 1H, OH-2′ , J2′ -2′ OH ) 5.9 Hz), 5.22
(bd, 1H, OH-3′ , J3′ -3′ OH ) 3.9 Hz), 4.65 (ddd, 1H, H-2′ , J1′ ,2′ )
5.4 Hz, J2′ ,3′ ) 5.5 Hz, J2′ -2′ OH ) 5.9 Hz), 4.10 (ddd, 1H, H-3′ ,
J2′ ,3′ ) 5.5 Hz, J3′ ,4′ ) 4.5 Hz, J3′ -3′ OH ) 3.9 Hz), 3.94-4.0 (m,
1H, H-4′ ), 2.62 (dd, 1H, 5′ -CH2), 2.48 (dd, 1H, 5′ -CH2), 2.18 (bs,
6H, N-(CH3)2). UV λmax, nm, pH 1, 256.3 (ε 15100), pH 7, 259.2
(ε 15500), pH 13, 259.7 (ε 15600). Anal. (C12H18N6O3·0.35CH3OH)
C, H, N.
5′ -Deoxy-5′ -methylthio-8-methyladenosine (24a). A solution of
8a (200 mg, 0.66 mmol) and sodium thiomethoxide (47 mg, 0.67
mmol) in 2 mL of anhydrous DMF was stirred for two days at
room temperature and then concentrated to dryness. The crude
product was puriﬁed by column chromatography using chloroform:
methanol (7:1) as eluent to yield 102 mg (49%). MS m/z 312 (M
+ H)+. 1H NMR (DMSO-d6) δ 8.09 (s, 1H, H-2), 7.12 (bs, 2H,
6-NH2), 5.77 (d, 1H, H-1′ , J1′ ,2′ ) 5.7 Hz), 5.38 (bd, 1H, OH-2′ ,
J2′ -2′ OH ) 4.4 Hz), 5.31 (d, 1H, OH-3′ , J3′ -3′ OH ) 4.2 Hz), 5.15
(bddd, 1H, H-2′ , J1′ ,2′ ) 5.7 Hz, J2′ ,3′ ) 5.7 Hz, J2′ -2′ OH ) 4.4 Hz),
4.20 (ddd, 1H, H-3′ , J2′ ,3′ ) 5.7 Hz, J3′ ,4′ ) 3.6 Hz, J3′ -3′ OH ) 4.2
Hz), 3.97-4.05 (m, 1H, H-4′ ), 2.74-2.92 (m, 2H, 5′ -CH2), 2.54
(s, 3H, 8-CH3), 2.03 (s, 3H, S-CH3).
5′ -Deoxy-5′ -dimethylsulfonio-8-methyladenosine bromide (25a).
Compound 24a (78 mg, 0.25 mmol) in a 2:1 mixture (4 mL) of
formic and acetic acid was treated witha2Msolution of
bromomethane in diethyl ether (5 mL) and stirred for six days in
darkness at room temperature. Solvents were removed in vacuo,
and a solution of the residue in water (10 mL) was extracted with
(3 × 10 mL) ether. The aqueous layer was concentrated to dryness.
The resulting product was dissolved in MeOH (10 mL), ﬁltered,
and treated with diethyl ether to precipitate out the salt. The salt
was ﬁltered, washed with ether, and dried in vacuo to give white
solid: yield 79 mg (78%). MS m/z 326 (M)+. 1H NMR (D2O) δ
8.24 (s, 1H, H-2), 6.03 (d, 1H, H-1′ , J1′ ,2′ ) 5.4 Hz), 5.29 (t, 1H,
H-2′ , J2′ ,3′ ) 5.7 Hz), 4.80 (t, 1H, H-3′ , J3′ ,4′ ) 4.8 Hz), 4.52-4.60
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CH2), 2.92 and 2.89 (2s, 6H, S-(CH3)2), 2.67 (s, 3H, 8-CH3).
5′ -Deoxy-5′ -dimethylsulfonio-8-methyladenosine chloride (25b).
Ion exchange resin (IRA-400, Cl- form) was washed repeatedly
with water and loaded into the column. The column was left
overnight and washed again repeatedly with water. The bromide
salt 25a (50 mg) was dissolved in water (1 mL) and put on the
column. The column was eluted with water very slowly in the dark.
The desired fractions were combined and lyophilized to yield 30
mg (68%). MS m/z 326 (M)+. 1H NMR (D2O) δ 8.24 (s, 1H, H-2),
6.03 (d, 1H, H-1′ , J1′ ,2′ ) 5.4 Hz), 5.29 (t, 1H, H-2′ , J2′ ,3′ ) 5.6
Hz), 4.80 (t, 1H, H-3′ , J3′ ,4′ ) 4.9 Hz), 4.52-4.60 (m, 1H, H-4′ ),
3.82-4.11 (m, 1H, 5′ -CH2), 3.75-3.83 (m, 1H, 5′ -CH2), 2.95 and
2.92 (2s, 6H, S-(CH3)2), 2.69 (s, 3H, 8-CH3). UV λmax, nm, pH 1,
258.8 (ε 15000), pH 7, 259.1 (ε 14700), pH 13, 263.5 (ε 13000).
Anal. (C13H20ClN5O3S·2H2O) C, H, N.
5′ -Deoxy-5′ -dimethylsulfonioadenosine bromide (25c). The
procedure described for 25a was used to prepare 25c from 24b
(58 mg, 0.19 mmol): yield 49 mg (65%). MS m/z 312 (M)+.
5′ -Deoxy-5′ -dimethylsulfonioadenosine chloride (25d). The pro-
cedure used was identical to that for 25b but starting with 25c.
The desired fractions were combined together and lyophilized to
yield 30 mg (44%). MS m/z 312 (M)+. 1H NMR (D2O) δ 8.29 (s,
1H, H-8), 8.27 (s, 1H, H-2), 6.12 (d, 1H, H-1′ , J1′ ,2′ ) 4.4 Hz),
4.99 (t, 1H, H-2′ , J2′ ,3′ ) 5.1 Hz), 4.55-4.62 (m, 2H, H-3′ , H-4′ ),
3.84-4.0 (m, 2H, 5′ -CH2), 2.95 and 2.93 (2s, 6H, S-(CH3)2). UV
λmax, nm, pH 1, 256.4 (ε 14300), pH 7, 259.6 (ε 14400), pH 13,
266 (ε 12300). Anal. (C12H18ClN5O3S·1.5H2O·0.1C2H5OH) C, H,
N, S.
Acknowledgment. This work was supported by grant PO1
CA-94000 from the National Cancer Institute. S.E.E. is indebted
to the W. M. Keck Foundation and the Lucille P. Markey
Charitable Trust. We thank the staffs of NE-CAT beamlines
8-BM and 24-ID-C at the Advanced Photon Source (NIH grant
RR-15301) and the F2 beam line of the Cornell High Energy
Synchrotron Source (NIH grant RR-01646) for providing beam
time. We thank Leslie Kinsland and Stephanie Brannon for
assistance in the preparation of this manuscript and thank Rachel
Robbins for her assistance in performing some of the confor-
mational searches reported in this manuscript.
Supporting Information Available: Elemental analyses used
to determine the degree of purity for all target compounds. This
material is available free of charge via the Internet at http://
pubs.acs.org.
References
(1) Hackert, M. L.; Pegg, A. E. Pyruvoyl-dependent enzymes. In Com-
prehensiVe Biological Catalysis; Sinnott, M. L., Ed.; Academic Press:
London, 1997; pp 201-216.
(2) Pegg, A. E.; Xiong, H.; Feith, D.; Shantz, L. M. S-adenosylmethionine
decarboxylase: structure, function and regulation by polyamines.
Biochem. Soc. Trans. 1998, 26, 580–586.
(3) Tabor, C. W.; Tabor, H. Polyamines. Annu. ReV. Biochem. 1984, 53,
749–790.
(4) Tabor, C. W.; Tabor, H. Methionine adenosyltransferase (S-adenos-
ylmethionine synthetase) and S-adenosylmethionine decarboxylase.
AdV. Enzymol. Related Areas Mol. Biol. 1984, 56, 251–282.
(5) Casero, R. A., Jr.; Celano, P.; Ervin, S. J.; Applegren, N. B.; Wiest,
L.; Pegg, A. E. Isolation and characterization of a cDNA clone that
codes for human spermidine/spermine N
1-acetyltransferase. J. Biol.
Chem. 1991, 266, 810–814.
(6) van Poelje, P. D.; Snell, E. E. Pyruvoyl-dependent enzymes. Annu.
ReV. Biochem. 1990, 59, 29–59.
(7) Wallace, H. M.; Fraser, A. V.; Hughes, A. A perspective of polyamine
metabolism. Biochem. J. 2003, 376, 1–14.
(8) Gerner, E. W.; Meyskens, F. L., Jr. Polyamines and cancer: old
molecules, new understanding. Nat. ReV. Cancer 2004, 4, 781–792.
(9) Pegg, A. E. Polyamine metabolism and its importance in neoplastic
growth and as a target for chemotherapy. Cancer Res. 1988, 48, 759–
774.
(10) Metcalf, B. W.; Bey, P.; Danzin, C.; Jung, M. J.; Casara, P.; Vevert,
J. P. Catalytic irreversible inhibition of mammalian ornithine decar-
boxylase (EC 4.1.1.17) by substrate and product analogues. J. Am.
Chem. Soc. 1978, 100, 2551–2553.
(11) Bewley, M. C.; Graziano, V.; Jiang, J.; Matz, E.; Studier, F. W.; Pegg,
A. E.; Coleman, C. S.; Flanagan, J. M. Structures of wild-type and
mutant human spermidine/spermine N
1-acetyltransferase, a potential
therapeutic drug target. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 2063–
2068.
(12) Alhonen-Hongisto, L.; Seppanen, P.; Janne, J. Intracellular putrescine
and spermidine deprivation induces increased uptake of the natural
polyamines and methylglyoxal bis(guanylhydrazone). Biochem. J.
1980, 192, 941–945.
(13) Basuroy, U. K.; Gerner, E. W. Emerging concepts in targeting the
polyamine metabolic pathway in epithelial cancer chemoprevention
and chemotherapy. J. Biochem. 2006, 139, 27–33.
(14) Fabian, C. J.; Kimler, B. F.; Brady, D. A.; Mayo, M. S.; Chang, C. H.;
Ferraro, J. A.; Zalles, C. M.; Stanton, A. L.; Masood, S.; Grizzle,
W. E.; Boyd, N. F.; Arneson, D. W.; Johnson, K. A. A phase II breast
cancer chemoprevention trial of oral alpha-diﬂuoromethylornithine:
breast tissue, imaging, and serum and urine biomarkers. Clin. Cancer
Res. 2002, 8, 3105–3117.
(15) Meyskens, F. L., Jr.; Gerner, E. W. Development of diﬂuoro-
methylornithine (DFMO) as a chemoprevention agent. Clin. Cancer
Res. 1999, 5, 945–951.
(16) Meyskens, F. L.; McLaren, C. E.; Pelot, D.; Fujikawa-Brooks, S.;
Carpenter, P. M.; Hawk, E.; Kelloff, G.; Lawson, M. J.; Kidao, J.;
McCracken, J.; Albers, C. G.; Ahnen, D. J.; Turgeon, D. K.;
Goldschmid, S.; Lance, P.; Hagedorn, C. H.; Gillen, D. L.; Gerner,
E. W. Diﬂuoromethylornithine Plus Sulindac for the Prevention of
Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled,
Double-Blind Trial. Cancer. PreV. Res. (Philadelphia, PA, U.S.) 2008,
1, 9–11.
(17) Raul, F.; Gosse, F.; Osswald, A. B.; Bouhadjar, M.; Foltzer-Jourdainne,
C.; Marescaux, J.; Soler, L. Follow-up of tumor development in the
colons of living rats and implications for chemoprevention trials:
assessment of aspirin-diﬂuoromethylornithine combination. Int. J.
Oncol. 2007, 31, 89–95.
(18) Williams-Ashman, H. G.; Schenone, A. Methylglyoxal bis(guanyl-
hydrazone) as a potent inhibitor of mammalian and yeast S-adenos-
ylmethionine decarboxylases. Biochem. Biophys. Res. Commun. 1972,
46, 288–295.
(19) Millward, M. J.; Joshua, A.; Kefford, R.; Aamdal, S.; Thomson, D.;
Hersey, P.; Toner, G.; Lynch, K. Multi-centre Phase II trial of the
polyamine synthesis inhibitor SAM486A (CGP48664) in patients with
metastatic melanoma. InVest. New Drugs 2005, 23, 253–256.
(20) Shantz, L. M.; Stanley, B. A.; Secrist, J. A. III; Pegg, A. E. Puriﬁcation
of human S-adenosylmethionine decarboxylase expressed in Escheri-
chia coli and use of this protein to investigate the mechanism of
inhibition by the irreversible inhibitors, 5′ -deoxy-5′ -[(3-hydrazino-
propyl)methylamino]adenosine and 5′ {[(Z)-4-amino-2-butenyl]methyl-
amino-5′ -deoxyadenosine. Biochemistry 1992, 31, 6848–6855.
(21) Danzin, C.; Marchal, P.; Casara, P. Irreversible inhibition of rat
S-adenosylmethionine decarboxylase by 5′ -{[(Z)-4-amino-2-butenyl]-
methyl amino}-5′ -deoxyadenosine. Biochem. Pharmacol. 1990, 40,
1499–1503.
(22) Ekstrom, J. E.; Matthews, I. I.; Stanley, B. A.; Pegg, A. E.; Ealick,
S. E. The crystal structure of human S-adenosylmethionine decar-
boxylase at 2.25 Å resolution reveals a novel fold. Structure 1999, 7,
583–595.
(23) Ekstrom, J. L.; Tolbert, W. D.; Xiong, H.; Pegg, A. E.; Ealick, S. E.
Structure of a human S-adenosylmethionine decarboxylase self-
processing ester intermediate and mechanism of putrescine stimulation
of processing as revealed by the H243A mutant. Biochemistry 2001,
40, 9495–9504.
(24) Tolbert, W. D.; Zhang, Y.; Cottet, S. E.; Bennett, E. M.; Ekstrom,
J. L.; Pegg, A. E.; Ealick, S. E. Mechanism of human S-adenosyl-
methionine decarboxylase proenzyme processing as revealed by the
structure of the S68A mutant. Biochemistry 2003, 42, 2386–2395.
(25) Tolbert, D. W.; Ekstrom, J. L.; Mathews, I. I.; Secrist, J. A. III; Kapoor,
P.; Pegg, A. E.; Ealick, S. E. The structural basis for substrate
speciﬁcity and inhibition of human S-adenosylmethionine decarboxy-
lase. Biochemistry 2001, 40, 9484–9494.
(26) Secrist, J. A., III. New substrate analogues as inhibitors of S-
adenosylmethionine decarboxylase. Nucleosides Nucleotides 1987, 6,
73–83.
(27) Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphos-
phine in synthesis and transformation of natural products. Synthesis
1981, 1–28.
(28) Khomutov, A. R.; Vepsalainen, J. J.; Shvetsov, A. S.; Hyvonen, T.;
Keinanen, T. A.; Pustobaev, V. N.; Eloranta, T. O.; Khomutov, R. M.
Synthesis of hydroxylamine analogs of polyamines. Tetrahedron 1996,
52, 13751–13766.
(29) Webb, R. R.; Kaneko, T. Synthesis of 1-(aminooxy)-4-[(3-nitro-2-
pyridyl)dithio]butane and 1-(aminooxy)-4-[(3-nitro-2-pyridyl)dithio]-
1406 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 5 McCloskey et al.2-butene, novel heterobifunctional crosslinking reagents. Bioconjugate
Chem. 1990, 1, 96–99.
(30) Kucznierz, R.; Grams, F.; Leinert, H.; Marzenell, K.; Engh, R. A.;
von der Saal, W. Tetrahydro-isoquinoline-based factor Xa inhibitors.
J. Med. Chem. 1998, 41, 4983–4994.
(31) Pankaskie, M.; Abdel-Monem, M. M. Inhibitors of polyamine bio-
synthesis. 8. Irreversible inhibition of mammalian S-adenosyl-L-
methionine decarboxylase by substrate analogues. J. Med. Chem. 1980,
23, 121–127.
(32) Borchardt, R. T.; Huber, J. A.; Wu, Y. S. Convenient preparation of
S-adenosylhomocysteine and related compounds. J. Org. Chem. 1976,
41, 565–567.
(33) Markham, G. D.; Norrby, P. O.; Bock, C. W. S-Adenosylmethionine
conformations in solution and in protein complexes: conformational
inﬂuences of the sulfonium group. Biochemistry 2002, 41, 7636–7646.
(34) Chang, G.; Guida, W. C.; Still, W. C. An Internal Coordinate Monte
Carlo Method for Searching Conformational Space. J. Am. Chem. Soc.
1989, 111, 4379–4386.
(35) Kolossvary, I.; Guida, W. C. Low-mode conformational search
elucidated: application to C39H80 and ﬂexible docking of 9-deaza-
guanine inhibitors into PNP. J. Comput. Chem. 1999, 20, 1671–1684.
(36) Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton,
M.;Cauﬁeld,C.;Chang,G.;Hendrickson,T.;Still,W.C.MacromodelsAn
Integrated Software System for Modeling Organic and Bioorganic
Molecules Using Molecular Mechanics. J. Comput. Chem. 1990, 11,
440–467.
(37) Ikehara, M.; Uesugi, S.; Kaneko, M. Bromination of adenosine
nucleosides and nucleotides. Chem. Commun. 1967, 17–18.
(38) Van Aerschot, A. A.; Mamos, P.; Weyns, N. J.; Ikeda, S.; De Clercq,
E.; Herdewijn, P. A. Antiviral activity of C-alkylated purine nucleo-
sides obtained by cross-coupling with tetraalkyltin reagents. J. Med.
Chem. 1993, 36, 2938–2942.
(39) Chattopadhyaya, J. B.; Reese, C. B. Reaction between 8-bromoad-
enosine and amines. Chemistry of 8-hydrazinoadenosine. Synthesis
1977, 725–726.
(40) Kohyama, N.; Katashima, T.; Yamamoto, Y. Synthesis of novel 2-aryl
AICAR derivatives. Synthesis 2004, 2799–2804.
(41) Long, R. A.; Robins, R. K.; Townsend, L. B. Purine nucleosides. XV.
Synthesis of 8-amino- and 8-substituted aminopurine nucleosides. J.
Org. Chem. 1967, 32, 2751–2756.
(42) Gani, D.; Johnson, A. W. The base-sugar conformation of certain
derivatives of adenosine. J. Chem. Soc., Perkin Trans. 1 1982, 1197–
1204.
(43) Otwinowski, Z.; Minor, W. Processing of x-ray diffraction data
collected in oscillation mode. Methods Enzymol. 1997, 276, 307–326.
(44) Bru ¨nger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros,
P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.;
Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L.
Crystallography & NMR system: A new software suite for macro-
molecular structure determination. Acta Crystallogr., Sect. D: Biol
Crystallogr. 1998, 54, 905–921.
(45) Jones, T. A.; Zou, J.-Y.; Cowan, S. W.; Kjeldgaard, M. Improved
methods for the building of protein models in electron density maps
and the location of errors in these models. Acta Crystallogr., Sect. A:
Found. Crystallogr. 1991, 47, 110–119.
(46) Emsley, P.; Cowtan, K. Coot: model-building tools for molecular
graphics. Acta Crystallogr., Sect. D: Biol. Crytallogr. 2004, 60, 2126–
2132.
(47) Kleywegt, G. J.; Jones, T. A. Databases in protein crystallography.
Acta Crystallogr., Sect. D: Biol Crystallogr. 1998, 54, 1119–1131.
(48) Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.;
Alagona, G.; Profeta, S., Jr.; Weiner, P. A new force ﬁeld for molecular
mechanical simulation of nucleic acids and proteins. J. Am. Chem.
Soc. 1984, 106, 765–784.
(49) Weiner, S. J.; Kollman, P. A.; Nguyen, D. T.; Case, D. A. An all
atom force ﬁeld for simulations of proteins and nucleic acids.
J. Comput. Chem. 1986, 7, 230–252.
(50) Ponder, J. W.; Richards, F. M. An efﬁcient Newton-like method for
molecular mechanics energy minimization of large molecules. J. Com-
put. Chem. 1987, 8, 1016–1024.
(51) Shantz, L. M.; Pegg, A. E. Assay of S-adenosylmethionine decar-
boxylase In Methods in Molecular Biology, Vol 79: Polyamine
Protocols; Morgan, D. M. L., Ed.; Humana Press Inc.: Totowa, NJ,
1998; pp 45-50.
(52) Kuhn, R.; Jahn, W. Thioethers and sulfoxides derived from adenosine.
Chem. Ber. 1965, 98, 1699–1704.
(53) Minnick, A. A.; Kenyon, G. L. General synthetic approach to stable
nitrogen analogs of S-adenosylmethionine. J. Org. Chem. 1988, 53,
4952–4961.
(54) Schmidt, R. R.; Schloz, U.; Schwille, D. Synthesis of 5′ -modiﬁed
adenosine derivatives. Chem. Ber. 1968, 101, 590–594.
JM801126A
Adenine C8-Substituted AdoMetDC Inhibitors Journal of Medicinal Chemistry, 2009, Vol. 52, No. 5 1407